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 ABSTRACT 
 
TB OR NOT TB: 




An estimated 9 to 14 million persons in the United States have latent tuberculosis infection 
(LTBI) and are therefore at risk for progression to active disease.1  Diagnosis and treatment for 
LTBI has been identified by the Centers for Disease Control and Prevention (CDC) and the 
Institute of Medicine as a  major strategy for elimination of tuberculosis (TB) in the U.S.2,3  
Approximately 200,000 - 300,000 Americans are treated for LTBI each year.4  This dissertation 
investigates patient characteristics that are associated with LTBI treatment completion and 
assesses the impact of a peer-based experimental intervention on adherence to, and completion 
of, LTBI treatment.  A review of the literature (Chapter 2) demonstrates that LTBI treatment 
completion rates in the U.S. and Canada generally fall below established targets and have been 
reported to range from 20 to 65% for a 6-month course of self-administered treatment.  
Associations between patient factors, clinic facilities, or treatment characteristics and adherence 
to LTBI treatment were found to be inconsistent across studies.  Additionally, adherence 
interventions have been developed but no single intervention has shown consistent effectiveness. 
 This suggests that a ‘one-size-fits-all’ approach to LTBI treatment adherence is not likely to 
succeed across all settings. 
The remainder of the dissertation focuses on predictors of LTBI treatment completion and the 
impact of a peer-based experimental intervention on adherence to, and completion of, LTBI 
treatment in two separate randomized controlled trials.  Data for these analyses are drawn from 
two sequential randomized controlled trials designed to compare a peer-based intervention to 
usual care for ensuring completion of treatment for LTBI in an urban clinic setting: the Pathways 
to Completion Study (recruitment from 1996 through 2000) as well as from the Tuberculosis 
Adherence Partnership Alliance Study (TAPAS ) (recruitment from 2002 through 2005).  Chapter 
3 describes the change in demographic, social, and behavioral characteristics between the two 
study populations.   
The first analysis (Chapter 4) examines predictors of LTBI treatment completion in this 
population.  Our results suggest that foreign birth, homelessness, marriage, and alcohol or drug 
use all influence completion of TLTBI through complex interactions.  Overall, married persons 
had better completion rates, but married foreign-born patients were substantially more likely to 
complete therapy than unmarried foreign-born patients.  Similarly, alcohol users were less likely 
to complete therapy, but homeless alcohol users were more likely to complete treatment than 
other homeless patients. The latter is probably an artifact of our clinic population, which includes 
patients from alcohol and substance abuse rehabilitation programs.  Residence in such programs 
may have a positive effect on treatment completion.  Race/ethnicity did not appear to be 
associated with treatment completion, although the differences between the two study 
populations made this difficult to assess. 
 Following from this, an analysis of the effectiveness of a peer-based experimental intervention 
on adherence to, and completion of, LTBI treatment in two separate randomized controlled trials 
(Chapter 5) finds peer support experimental intervention to be very effective in the Pathways 
population but not in the TAPAS population where completion rates increased substantially for 
both the intervention and control groups.  The power for detecting an intervention effect in 
TAPAS was reduced by the higher than expected completion rates in both groups; however, the 
effect of the TAPAS intervention is statistically significant in the adherence model.  Adherence 
analysis in TAPAS suggests that it is important to intervene early in the treatment as the first two 
months of treatment present a danger period where patients tend to default treatment.  The most 
common reasons reported for not adhering to treatment were “forgot”, “ran out of medications”, 
and “other priorities.”  Identifying reasons for missing medications can suggest possible foci for 
interventions in the early months, such as weekly reminders to take the medications and ensuring 
that prescriptions are refilled on schedule. 
Taken together, the findings of this research have significant implications for improving 
adherence to and completion of LTBI treatment.  Currently, the primary intervention for 
improving LTBI adherence consists of educational programs to increase knowledge and modify 
attitudes.  Our findings suggest that tangible assistance would be more effective in encouraging 
treatment completion.  Additionally, adherence analysis in TAPAS suggests that it is important 
to intervene early in the treatment.  Close follow-up of patients during the first two months of 
treatment, with prompt intervention to encourage completion among those stopping treatment, 
may yield better outcomes and reduce costs over the long term. 
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 Consensus is building that the identification and treatment of latent tuberculosis infection (LTBI) 
among the reservoir of latently infected persons is the key to the elimination of tuberculosis in 
North America.1,2  An estimated 9 to 14 million persons in the United States have LTBI placing 
them at risk for progression to active disease, and approximately 200,000 - 300,000 Americans 
are treated for LTBI each year.3,4  Targeted testing in high risk populations has proved to be an 
important approach to the identification of at-risk subjects.  While these TB control strategies are 
currently being refined with the use of interferon-gamma release assays in place of tuberculin 
skin testing, the basic strategies for identifying at-risk persons are time-tested.  Less clear is what 
guidance to offer providers for targeting factors that influence completion so that we could help 
all patients complete treatment and what interventions may be effective in promoting adherence 
and completion of treatment.     
In the context of moving from TB control to TB elimination in the United States, adherence to 
and completion of treatment of LTBI are crucial factors in the success of eliminating TB in the 
U.S.  Therefore, it is important to elucidate factors associated with adherence and completion of 
LTBI treatment.  Identifying barriers to adherence and completion of LTBI treatment will 
facilitate the development of effective, culturally competent interventions.  Furthermore, it is 
important to evaluate new interventions, based on patients’ perceptions and behavior, for 
improving adherence to and completion of LTBI treatment.   
Starting in 1955, several reasonably large, adequately conducted studies have examined the 
efficacy of isoniazid in the prevention of tuberculosis among persons without HIV infection.5  
These clinical trials have shown the effectiveness of isoniazid ranging from 92 percent in 
preventing active tuberculosis in patients when adherence is high, to 26 percent when adherence 
is low.  The current recommended standard therapy for LTBI, which consists of 9 months of 
2
 daily isoniazid taken in a 12-month period, has an efficacy of more than 90%.6  A large multi-
site study reported recently that treatment completion rates of the standard 9-month isoniazid 
regimen range from 30-60%,7 far below established targets of 80-85% completion.8     
Poor adherence to treatment for LTBI and corresponding modest treatment completion rates 
impede efforts to eliminate TB in this country.  This issue is particularly critical in Harlem, a 
community where the rates of TB greatly exceed the national average (16.7/100,000 vs. 
4.2/100,000 in 2008, respectively)9 and the concomitant HIV epidemic results in a large 
population vulnerable to TB.  The barriers to adherence in this population are significant because 
of multiple challenges to accessing health care services, including language barriers, 
transportation, and lack of knowledge about available no-cost health services.  The social stigma 
attached to many infectious diseases gives rise to fears of discrimination and isolation, and often 
inhibits people from seeking testing and treatment services.  Another significant barrier in this 
population is fragile and inadequate social support networks.  Furthermore, the large proportion 
of immigrants in Harlem may share with the general population a low awareness of the need for 
preventive health behaviors, such as completion of treatment for LTBI.  High substance use rates 
in the community may further contribute to non-adherence risk.   
The objectives of this dissertation were 1) to critically review the literature on adherence to 
treatment of LTBI, 2) To identify the change in demographic, social, and behavioral 
characteristics of patients undergoing treatment for LTBI in the Chest Clinic at Harlem Hospital 
between 1996 and 2005, 3) to identify patient demographic, social, and behavioral characteristics 
that are associated with LTBI treatment completion, and 4) to assess the impact of a peer-based 
experimental intervention on adherence to and completion of LTBI treatment in a general clinic 
population in an urban setting in the U.S.  Data for the dissertation are drawn from the Pathways 
3
 to Completion Study (recruitment from 1996 through 2000) as well as data from the Tuberculosis 
Adherence Partnership Alliance Study (TAPAS ) (recruitment from 2002 through 2005).  
Pathways and TAPAS were sequential randomized controlled trials designed to compare a peer-
based experimental intervention to usual care for ensuring completion of treatment for LTBI in 
an urban clinic setting. 
The dissertation is comprised of six chapters.  After this introduction, chapter 2 reviews the 
literature on adherence to treatment of LTBI focusing on the following areas: review of LTBI 
treatment completion rates in a variety of settings and regimens, discussion of issues in the 
measurement and analysis of adherence, review of known predictors of adherence to LTBI 
medications, and review and examination of different interventions developed to improve 
adherence to and completion of LTBI treatment.  Chapter 3 describes changes in demographic, 
social, and behavioral characteristics of 610 patients undergoing treatment for LTBI in the Chest 
Clinic at Harlem Hospital between 1996 and 2005.  Chapter 4 examines predictors of LTBI 
treatment completion; foreign birth, homelessness, and current substance use were hypothesized 
a priori to be predictors for LTBI treatment non-completion.  Chapter 5 assesses the impact of a 
peer-based experimental intervention on adherence to and completion of LTBI treatment in two 
sequential randomized controlled trials; it was hypothesized that the intervention would have a 
positive effect on LTBI treatment completion rates.  The dissertation ends with a short 
concluding chapter discussing how these results, taken together, can contribute to our 
understanding of factors associated with completion of LTBI treatment and the evaluation of 
effective interventions, delivered in a culturally competent manner, for improving adherence to 
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 Chapter 2:  
Adherence to treatment for latent tuberculosis infection: systematic review of 





This chapter has been published as: 
Hirsch-Moverman Y, Daftary A, Franks J, Colson PW. Adherence to treatment for latent 
tuberculosis infection: systematic review of studies in the U.S. and Canada. International Journal 
of Tuberculosis and Lung Disease,12(11):1235-1254, 2008. PMID: 18926033 
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 SUMMARY 
BACKGROUND: There is renewed attention to the critical role of successfully treating latent 
tuberculosis infection (LTBI) in reducing the overall impact of tuberculosis (TB).  However, 
levels of treatment adherence are consistently low in industrialized countries such as the U.S. and 
Canada. 
OBJECTIVE: A systematic review of studies in the United States (U.S.) and Canada was 
undertaken to analyze methods of measuring LTBI treatment adherence, rates of adherence and 
completion of LTBI treatment in different settings and with different interventions, and 
predictors of LTBI treatment adherence. 
METHODS: PUBMED, MEDLINE, and PsycINFO electronic databases were searched for 
quantitative studies published between 1997 and 2007.  Full texts of articles were reviewed for 
data abstraction, and studies were critically examined for their methodology and rigor.  This 
review presents outcomes from 78 studies.  
RESULTS: Adherence and completion rates of treatment of LTBI are suboptimal across high-
risk groups, regardless of regimen.  LTBI treatment completion rates in the U.S. and Canada 
generally fall below established targets and have been reported to range from 20 to 65% for a 6-
month course of self-administered treatment; a few smaller studies were able to achieve higher 
completion rates.  Associations between adherence and patient factors, clinic facilities, and 
medication regimen characteristics were found to be inconsistent across studies.  Adherence does 
not appear to be related to patients’ age, gender, place of birth, or race.  Several adherence 
interventions have been developed to improve LTBI treatment adherence in the U.S. and 
Canada; however, no single intervention has shown consistent effectiveness.  Incentives, 
contextual considerations, and professional adherence counseling were successfully applied to 
7
 improve adherence, but they need to be tested for reliability in diverse settings.  Interventions 
using DOT, education programs, and peer support report mixed findings and warrant further 
exploration in the context of TLTBI. 
CONCLUSION: LTBI must be effectively treated if the goal of TB elimination is to be realized. 
Consistently employing tools for measuring and improving adherence are fundamental.  
Identifying barriers to adherence and treatment completion will facilitate the development of 
effective, appropriate interventions.  A ‘one-size-fits-all’ approach to TLTBI adherence is not 
likely to succeed across all settings.  Innovative approaches can inspire future interventions and 




Recognition is growing within the medical community that the promise of efficacious therapies 
to treat long-term and chronic disease conditions cannot be met unless patients consistently 
adhere to prescribed drug regimens.1 Adherence to treatment influences individual health 
outcomes and the overall cost of health care and, in the case of communicable infections such as 
tuberculosis (TB) and the human immunodeficiency virus (HIV), can influence the emergence 
and spread of resistant strains.   
In TB, efforts to improve adherence have focused primarily on treating TB disease.  Several 
factors contribute to the public health prioritization of adherence to TB treatment: (1) TB is often 
highly contagious; (2) non-adherence prolongs the infectious phase; (3) non-adherence augments 
the development and spread of drug-resistant organisms; and (4) the human and fiscal costs of 
treating drug-resistant TB are substantial.  Nonetheless, there are challenges associated with 
treatment adherence (Table 1), which have prompted comprehensive adherence interventions for 
TB disease. 
In contrast, treatment for latent TB infection (TLTBI) lacks a similar sense of public health 
urgency:  LTBI is not contagious and it is not associated directly with the development of 
resistant strains. Instead, patients, and in some cases providers, must be convinced of the need to 
treat a non-contagious infection that may never develop into active disease and to use prolonged 
therapy that may cause potential adverse effects.  Initiating TLTBI in the United States (U.S.) 
and Canada is especially challenging among foreign-born persons with a history of Bacillus 
Calmette-Guérin (BCG) vaccination, who originate from TB endemic regions and often lack 
trust in the accuracy of the LTBI diagnosis.  Successful adherence to LTBI treatment is even 
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 more challenging than it is in the setting of treatment of active infection; Table 1 compares these 
challenges and the impact on adherence to TLTBI. 
Approximately 10% of persons with LTBI go on to develop TB disease, the risk being much 
higher among HIV-infected persons.2-4  The World Health Organization, together with the 
Centers for Disease Control and Prevention (CDC) and the American Thoracic Society (ATS), 
acknowledge the critical role of TLTBI in mitigating the overall impact of TB.2,5,6 A key 
objective of the national strategy for TB control in the U.S. aims for 85% of high-risk persons 
with LTBI to successfully complete a course of treatment.7 Clinical trials have shown TLTBI 
with 6 months of isoniazid results in a 69% reduction in TB, and 12 months of treatment, a 93% 
reduction.  In sub-group analyses the maximum beneficial effect of isoniazid, when considering 
cost-effectiveness and feasibility, is likely achieved at 9 months assuming high rates of 
adherence.2  However, levels of adherence are found to be consistently low in industrialized 
countries such as the U.S. and Canada that routinely treat LTBI.   
We have undertaken a systematic review of studies in the U.S. and Canada to analyze the 
following: (1) measurement of LTBI adherence; (2) LTBI treatment completion rates; (3) 
predictors of LTBI adherence; and (4) LTBI adherence interventions.  We conclude with some 
insights and implications for further research. 
 
METHODOLOGY 
PUBMED, MEDLINE, and PsycINFO electronic databases were searched for quantitative 
studies using the following terms: (tuberculosis OR latent tuberculosis) AND (preventive therapy 
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 OR chemoprophylaxis OR treatment) AND (adherence OR compliance OR completion).  The 
search was limited to studies published in peer-reviewed journals in English between 1997-2007, 
including adult populations in the U.S. or Canada.  Over 800 study titles and abstracts were 
screened based on pre-defined inclusion and exclusion criteria (Table 2).   
Titles and abstracts of identified citations were used to exclude studies that clearly did not meet 
the inclusion criteria.  If a study was judged to be potentially eligible for inclusion, the full paper 
was obtained.  Full texts of articles of possible relevance were reviewed independently for data 
abstraction.  Studies were critically analyzed for their methodology and rigor, including study 
design, sample group(s), operational definitions of outcome variables/measures, and data 
analysis.  A total of 78 studies met the inclusion criteria and were included in this review.  Ethics 
approval was not required for this review. 
Definitions  
Treatment 
In 2000, the ATS/CDC guidelines for TLTBI were revised to recommend 6 or 9 months of 
isoniazid (INH), regardless of patients’ HIV status.2  In studies examined for this review, unless 
otherwise noted, TLTBI was with 6 months of INH (6INH); persons with known HIV-infection 
were treated with 12 months of isoniazid (12INH).  Findings from studies using shorter courses 
of rifampicin (RIF), pyrazinamide (PZA), rifabutin and/or INH are noted as such.  Numbers 




 Treatment completion rate 
We have used treatment completion rates to serve as an operational measure of adherence.  
TLTBI completion was defined as having ingested at least 80% of prescribed doses, based on the 
criteria employed within reviewed articles.  In calculating a completion rate, some studies used 
the number of persons diagnosed with LTBI or the number eligible for treatment as the 
denominator.  To allow for reliable comparisons across studies, completion rates noted in this 
review represent the number completing therapy over those initiating therapy.  Therefore, where 
the completion rate was recalculated to conform to this standard, rates presented here may be 
higher than those in the original published study. 
Directly observed therapy (DOT) 
DOT is defined as the supervised ingestion of patients’ prescribed doses.  This supervision is 
typically done by a public health advisor or nurse. 
Self-administered therapy (SAT) 
SAT is defined as patients’ self-administration of prescribed doses.  
Significance 
All findings reported to have statistical significance are within the 95% confidence interval range 
or p≤0.05 level.  When sequential levels of analysis were applied to study data, findings resulting 





Accurate measurement of adherence is necessary to ensure that therapeutic outcomes can be 
attributed to the recommended treatment.  While no “gold standard” exists for measuring 
adherence,1,8,9 several direct and indirect measurement methods are used.  Direct methods are 
generally more objective, yielding more reliable assessments of adherence, but each method has 
limitations.10 Benefits and drawbacks of these techniques with respect to TLTBI are discussed 
below and summarized in Table 3. 
Direct methods 
Directly observed therapy 
DOT has been used in TLTBI.11-31 However, there is no public health mandate justifying its 
routine use for TLTBI.  Furthermore, it is expensive, has infrastructural requirements, and may 
be perceived as paternalistic or intrusive by patients.32   
Drug-level measurement 
Drug-levels or their metabolites in body fluids provide an objective measure of adherence.  
Urine-testing for INH metabolites has been used to measure adherence to TLTBI.33-35 This 
method assesses only the most recently ingested dose and results may be influenced by inter-
subject pharmacokinetic variability and drug/food interactions.  It is unsuitable for multiple drug-
regimens, and high laboratory costs render it impractical in most clinical settings.9,36,37 
 
13
 Clinic attendance 
Monitoring adherence to clinic visits is inexpensive and often applied in LTBI-
settings.11,21,22,34,38-44 However, while poor clinic attendance is a good indicator of non-




Interviewer-based patient self-reports can accurately estimate adherence behavior.8,9,36,37 Self-
report is a quick, inexpensive measure of adherence, and is the only measure that can help 
identify reasons for non-adherence.8,37 It has been used for LTBI patients on self-administered 
therapy.13,28,33,34,41,45-53 Limitations of self-report measures include recall bias, social desirability 
bias, and overestimation,8,9,36,37 all of which result in low sensitivity, although self-report is 
thought to have high specificity for non-adherence.37 Self-report better identifies non-adherers 
than good adherers.8 To improve accuracy, studies have limited recall to recent time periods, or 
implemented the concurrent use of pill diaries, audio computer-assisted self-interviews, and 
adherence questionnaires.8,36,37  
Provider assessment 
Providers tend to overestimate adherence; their assessments of non-adherence have low 
specificity and low sensitivity,8,36,37 and are generally used as adjunct measures in LTBI-
settings.44 
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 Electronic monitoring device (EMD) 
Electronic drug monitoring is considered among the most accurate and objective adherence 
measures.36,37,54 Prescription bottles equipped with the Medication Event Monitoring System 
(MEMS®) cap, or Smart-cap®, utilize an electronic device that records dates and times at which 
the cap is removed.  EMD’s may be easily applied in clinical practice, and have proven to be 
reliable assessors for adherence to TLTBI.33,55,56 They have also been used to validate or detect 
overestimation of drug intake by alternative measures including self-reports, provider estimates, 
pill-counts, and urine-tests.33,36,54,55 However, EMD’s do not prove dose ingestion, nor do they 
track the number of pills removed or ingested at each opening.8,9 They are subject to decanting 
and pocket-dosing, or dose removal without simultaneous dose intake.8,37 EMD’s are perceived 
as cumbersome, costly, subject to malfunctioning,8,36,37 unsuitable for multiple drug-regimens 
and may interfere with concurrent use of pillboxes.8,36,54  
Pill count  
Pill counting is inexpensive and has been used in TLTBI.13,26,33-35,41,44,46,57 However, pill count 
cannot confirm dose ingestion at prescribed time intervals, and is subject to 
overestimation.8,9,36,37 It is time-consuming and seldom used because of difficulty ensuring that 
pill bottles are returned to clinics.  Conducting pill counts during unannounced home visits may 
yield better info,37 but accuracy likely declines over subsequent visits. 
Prescription refill rate 
Pharmacy databases can monitor prescription refill and default rates.  TLTBI adherence has been 
assessed by patients’ timely collection of medications from TB clinics,11,21,22,27,28,44,48,58-61 but is 
15
 impractical if patients access several pharmacies.36 Refill rates are subject to low precision and 
are unable to prove dose ingestion.8,9,36,37 
Composite measures 
Studies have used a combination of methods to assess TLTBI adherence.13,26,28,33-35,41,44,48 There 
is some evidence that composite adherence scores, computed from several adherence measures, 
may estimate adherence better than any single method.1,8,9,34,37,54 An Adherence Index was 
computed in one LTBI-related study.34 However, the validity of this method depends on that of 
its individual components and studies demonstrate mixed results regarding its efficacy compared 
to self-report or DOT alone.9,54 Its feasibility may be restricted to research, rather than clinical 
settings.8,54 
 
LTBI TREATMENT COMPLETION RATES 
While adherence to treatment of TB disease has received substantial attention in the literature, 
relatively less data have accumulated on adherence to TLTBI.  Existing information suggests that 
completion and adherence rates are low across patient populations and treatment regimens (Table 
4). 
Adherence to treatment with INH 
Completion rates from interventional studies designed specifically to improve adherence to 
TLTBI are discussed later.  Unless otherwise noted, all patients in this sub-section were 
prescribed 6INH, or 12INH for those with known HIV infection, by SAT. 
16
 Contacts  
Contacts of infectious TB cases are at increased risk for developing active disease and present an 
opportunity for preventing future TB cases.5 In several studies examining contact investigations 
in large or selected areas of the U.S., completion rates varied between 35-64%.62-67 Others 
examined contact investigations in a specific state, city, or community; completion rates varied 
between 50-89%.68-76 
Prison and jail inmates 
Tuberculosis remains a serious problem in correctional facilities.  Medical and social risk factors 
of inmates render them at higher TB risk than the general population.2,5 TLTBI completion rates 
within correctional facilities ranged between 32-61%.46,77,78 
Foreign-born 
An increasing proportion of TB in the U.S. occurs among the foreign-born.79 Targeted TLTBI 
for recent immigrants from TB-endemic countries may prevent an estimated 1,300 cases of TB 
per year in the 5 years after immigration.79 Several studies were conducted among recent 
immigrants from TB-burdened countries; completion rates varied from 22-90% depending on 
study size and type of population.38,41,45,48,51,53,58,59,80-84; one study with 9INH found a completion 






Injection drug-users are at increased risk for progression from LTBI to active TB because of 
their increased risk for HIV infection.2,3,5 Studies of this population focused on treatment 
effectiveness or hepatotoxicity.  Completion rates varied greatly between 39-70%.12,19,57,85 
Other high-risk populations 
In several studies evaluating TLTBI among the homeless, healthcare workers, and patients of 
HIV-clinics, completion rates ranged from 27-82%.39,40,60,86-89 
Adherence to alternate regimens 
Isoniazid has been the foundation of TLTBI for over 40 years.  Its use has been compromised 
owing to the required lengthy treatment, its reputation for hepatotoxicity, and increasing influx 
of foreign-born persons from countries with high prevalence of INH resistance.90 In 2000, 
shorter course regimens of RIF with or without PZA were recommended as acceptable 
alternative regimens for TLTBI.2  
RIF regimens 
When compared with 9INH, better completion rates with 4RIF were found in retrospective 
medical record reviews,44,91 as well as in a randomized trial.56 Those studies reported completion 
rates between 72-91%.  While not evaluated or recommended in the U.S. as an acceptable 
alternative regimen, combinations of INH/RIF have been studied in Europe and Canada.  In a 
Canadian study, treatment completion with 6INH/RIF was 82%.26   
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 RIF/PZA regimens 
The basis for the recommendation of RIF/PZA regimens was a large, open-label, randomized, 
multi-center trial in HIV-infected persons comparing 12INH to 2RIF/PZA.92 The study found 
2RIF/PZA to be similar in efficacy to 12INH, with a significantly higher completion rate.  
Following the new recommendation, 2RIF/PZA, either alone or in comparison to INH, was 
studied in high-risk populations.  Some comparative studies found the shorter regimen to be 
associated with higher completion rates,27,49,93 while others have found similar rates of 
completion.35,52,94 Studies that focused on the RIF/PZA regimen alone found completion rates of 
46-91%.14,23-25,28,50,95,96 In 2003, RIF/PZA regimens were withdrawn by the ATS/CDC for safety 
reasons.97 
  
PREDICTORS OF ADHERENCE TO LTBI MEDICATIONS  
Several factors relating to patients, clinic facilities, and treatment characteristics have been 
shown to impact adherence to TLTBI (Table 5). 
Demographic characteristics  
Many studies have examined associations between demographic factors and adherence to 
TLTBI.  Adherence does not appear to be related to patients’ age, gender, place of birth, or race.  
In the few instances of a significant association, studies exhibit inconsistent results.  Age has 
been positively associated with treatment completion in different age groups: in persons >65 
years old,39 in those <35,48 and with increasing age.17,25 Gender associations have also varied in 
direction, with completion reported better in women than men in some studies,41,48 and vice versa 
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 in others.14,20 White Hispanic ethnicity was a significant predictor of completion.48 Place of birth 
also demonstrates contradictory findings.  Two studies found TLTBI completion to be higher in 
foreign-born persons than in US-born persons.39,48 Another study reported better completion 
rates in both U.S.-born and foreign-born persons in the U.S. more than 5 years compared to new 
immigrants.77 Failure to complete has also been associated with specific birthplaces.58   
Patient-related factors 
Recent exposure to TB,64 marriage,17 social support,17 and higher education17,77 have been 
positively associated with TLTBI adherence. Conversely, injection drug use,14 excessive alcohol 
use,48 daily alcohol/drug use,17 alcohol use by men,40 lack of health insurance,17 
unemployment,14,44 prior BCG vaccination,60 and recent hospitalization17 have been associated 
with failure to complete.  Additionally, attitudes in support of treatment completion,17 intention 
to adhere,17 and perceived risk of progressing to active TB59 were found to be associated with 
better adherence.  Three studies found patients with stable housing had better TLTBI 
adherence,20,21,42 while homelessness has been found to be associated with better completion,17 or 
worse completion.48  
Clinic characteristics  
Interventions that enhance clinic characteristics have influenced TLTBI adherence, to the extent 
that they adequately address patient needs.  Outcomes from these adherence interventions, 
including trials with directly observed therapy, incentives, education programs, context, 
counseling and support services, are discussed below in the section on adherence interventions.   
20
 Treatment characteristics  
TLTBI can lead to adverse drug effects including hepatotoxicity, skin rash, and nausea.  Patients’ 
concerns about drug toxicity and side effects have been associated with lower treatment 
completion,45,48 as has onset of clinical symptoms.25 Reluctance to undergo venipuncture in the 
course of monitoring for side effects was also found to be a significant predictor of non-
completion.59 
Parallel medical therapies impact TLTBI adherence.  Concurrent methadone treatment has been 
associated with better completion,11 or lower completion,35 whereas concomitant medication use 
by women has been associated with failure to complete TLTBI.40  
Shorter courses of TLTBI, including combinations of RIF, PZA, rifabutin and/or INH, have been 
associated with improved adherence; these outcomes were discussed earlier. 
 
LTBI ADHERENCE INTERVENTIONS 
The preceding section highlights risk factors for non-adherence identified in TLTBI studies.  
Several authors have argued that adherence behavior is influenced by complex interactions 
among predictive factors, rather than resulting directly from the factors themselves.98,99 Health 
behavior theories generally attempt to characterize these interactions: for instance, the Health 
Belief Model highlights the perceptual foundations of health behavior and posits that behavior is 
motivated by outcome expectations.98 It has guided TB screening and treatment programs that 
attempt to influence individual beliefs about disease susceptibility, severity, treatment efficacy 
and benefits, and perceived barriers to care, such as difficulties accessing services and 
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 medication side effects.100,101 In TLTBI, however, interventions seldom address the underlying 
processes by which multiple factors interact to influence adherence or non-adherence. 
Several adherence support interventions not explicitly based on health behavior models have 
addressed individual or groups of factors associated with low TLTBI completion rates in North 
America (Table 6).  However, no single intervention has shown consistent effectiveness.    
Alternative regimens 
Findings from studies comparing different drug regimens are discussed above (see treatment 
characteristics).  Generally, observed improvements in adherence with shorter courses, including 
combinations of RIF, rifabutin or PZA, have been outweighed by their greater risk for 
hepatotoxicity.  
Direct observation 
DOT has historically been used to promote adherence to multi-drug TB regimens.1 A recent 
review on TB treatment found no evidence that DOT generated better cure or completion than 
SAT, regardless of the type of direct observation provided.102 DOT has been tested for LTBI 
monotherapy to a much lesser degree, with varied results. 
Nolan et al.30 followed 262 jail inmates who volunteered to receive DOT for LTBI while in jail 
and upon their release.  Treatment completion among 157 inmates located post-release was 
significantly higher for those on DOT compared to SAT (60% vs. 29%).  In a study with 111 
opioid-dependent patients, Batki et al.11 found completion was significantly higher for those 
randomly assigned to DOT with methadone therapy compared to patients on SAT (60-77% vs. 
13%).  White et al.22 retrospectively reviewed 1,079 medical records for LTBI patients before 
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 and after institution of a DOT program.  Adherence improved overall, with patients on DOT 
twice as likely to complete treatment as those prescribed SAT (70% vs. 48%).  Heal et al.13 
conducted a retrospective review of 608 aboriginal patients in British Columbia receiving 
TLTBI.  Completion was significantly higher with DOT than SAT (75% vs. 61% for 6INH, 51% 
vs. 37% for 12INH). 
In a randomized controlled trial with 300 injection drug-users, Chaisson et al.33 compared DOT 
to SAT with or without peer education.  There were no significant differences in completion 
between the groups (overall 79%). 
Tulsky et al.21 tested several LTBI adherence interventions with 118 homeless/marginally-
housed patients.  Those assigned to DOT with incentive had the highest completion rate 
compared to patients on DOT with peer support, or on SAT alone (44% vs. 19-26%).  In a pilot 
intervention, Lorvick et al.15 showed 89% treatment completion among 27 injection drug-users 
receiving DOT with incentives.  O’Connor et al.18 evaluated 39 opioid-dependent drug-users in 
rehabilitation.  Completion by DOT was 72%, when liquid-INH was dispensed or mixed into 
daily doses of methadone.  Similarly, Snyder et al.31 showed 75% completion among 378 drug-
users receiving DOT with methadone.  These studies did not directly compare DOT to SAT.  
The literature shows that the effectiveness of DOT can be enhanced by implementing concurrent 
interventions such as drug rehabilitation,11,18,31 incentives,15,16,20,22,31 outreach,22,31 professional 
management,17 and shorter waiting times.22,31 But notwithstanding the tendency to observe 
higher adherence with DOT than SAT, actual completion rates in comparative studies remain 




Incentives can enable treatment initiation and help overcome barriers to completion.15,16,20,21 
Malotte et al.16 showed that incentives were superior to outreach in improving LTBI adherence; 
163 injection drug-users were randomly assigned to $5 and off-site DOT, $5 and community-site 
DOT, or off-site DOT alone.  Off-site DOT, or active outreach, was provided at venues chosen 
by participants, but deterred adherence due to their concerns of being publicly identified as 
having TB.  Treatment completion was significantly higher among the incentives groups, 
regardless of outreach services (53-60% vs. 4%).  Tulsky et al.21 found incentives more effective 
than peer health advisors.  In a randomized controlled trial with 118 homeless/marginally-housed 
persons, those receiving $5 were significantly more likely to complete supervised treatment 
(44% vs. 19%).  
In three studies, monetary incentives were given across all comparison groups.15,17,33  Their 
effect on adherence could not be separated from the effect of the primary intervention. 
Mangura et al.35 studied the effect of non-monetary incentives on 55 HIV-positive homeless 
injection drug-users.  Completion, defined as ≥70% adherence, was significantly higher among 
patients who requested and received a nutritional supplement (76% vs. 31%). 
Questions around the most suitable type of incentive and time for distribution have been briefly 
explored.  In their factorial randomized controlled trial, Chaisson et al.33 compared adherence in 
300 injection drug-users assigned to receive $10 at the end of each month of successful treatment 
or credited $10 monthly but paid only at the end of successful treatment.  Completion was not 
significantly different between the immediate and deferred incentive groups (overall 79%).  
Tulsky et al.20 randomly distributed $5 cash or equivalent-valued grocery/fast-food/phone/bus 
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 coupon among 119 homeless persons commencing TLTBI by DOT.  Assignment of a cash or 
non-cash incentive was not significant in determining completion of therapy (overall 86%).  
Education 
Educational interventions show comparable,77 if not greater,42 efficacy in TLTBI adherence than 
the use of incentives – findings that may relate to the incentive value, timing of disbursement, 
and quality of education offered.  In 1998-99, White et al.42 studied 325 of 558 inmates who 
were released from jail subsequent to initiating TLTBI while incarcerated.  They were randomly 
assigned to receive bi-monthly education sessions in jail, $25 equivalent in food/transport 
vouchers upon attendance of their first clinic visit post-release, or neither intervention.  
Treatment completion was significantly higher among inmates in the education group, with no 
difference between incentive and control groups (23% vs. 12%).  Group overall remained a 
significant predictor of completion in a conditional analysis with 104 released inmates who 
completed their first clinic visit.  These 104 inmates were later compared against 164 inmates 
who received a single education session upon release in 2002-03.103 Their completion rates were 
similar (overall 51%). 
A five-year follow-up study with 557 of 558 inmates who initiated TLTBI in 1998-99 found no 
significant difference in completion between those originally assigned to the education, incentive 
or control groups (overall 32%).77 Failure of the education intervention in persisting as a 
significant predictor of adherence was attributed to lack in continuity of care for inmates released 
into the community while still receiving TLTBI.  Both follow-up studies suggest that the role of 
education in TLTBI adherence has yet to be clearly defined. 
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 Contextual considerations 
Several interventions have attempted to address patients’ contextual circumstances.  Goldberg et 
al.47 found case managers matched to patients’ cultural backgrounds significantly improved 
adherence with 389 refugee patients, when compared to historical controls (82% vs. 37%).  At a 
health unit serving foreign-born workers who commonly assumed aliases, Kim et al.29 reported 
outcomes of a no-name tracking system.  TLTBI completion rose from 48 to 64% over three 
years.  Batki et al.11 found methadone-maintenance significantly enhanced treatment completion 
among drug-using patients (60-77% vs. 13%). 
Professional counseling 
Counseling services have been offered to support patients’ motivation and self-efficacy to 
complete treatment.  Nyamathi et al.17 evaluated a site-randomized nurse-managed intervention 
with 520 homeless persons, based on integration of a comprehensive health-seeking and coping 
paradigm into adherence counseling, outreach, and prevention of loss to follow-up.  The 
intervention significantly improved treatment completion compared to standard adherence 
counseling (62% vs. 39%), despite universal distribution of incentives and DOT.  Similarly, 
Tavitian et al.61 assessed a pharmacist-managed intervention for healthcare workers, promoting 
refill reminders, medication counseling, and drug-monitoring.  SAT completion rates rose from a 
historic 1% pre-intervention to 76-93% in years following the intervention. 
Among 72 opioid-using patients on DOT and methadone, Batki et al.11 found TLTBI completion 
was not boosted in those randomly assigned to receive substance-abuse counseling (overall 
68%).  That counseling targeted substance abuse rather than adherence management may help 
explain the contrary outcome. 
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 Peer support 
Peer workers, often matched on the basis of race, ethnicity or sexual orientation, have credibility 
with patients from sharing common reference groups or having faced similar challenges.104 
Findings from LTBI-related studies are mixed. 
In their factorial randomized controlled trial with injection drug-users, Chaisson et al.33 
employed peer workers who were former drug-users, had completed TLTBI, and had received 
extensive training on HIV and TB counseling.  Adherence assessed by pill count or INH urine-
testing generated no measurable differences (overall 78%).  However, among 201 participants on 
SAT, electronically measured adherence was significantly higher among those assigned to peer 
workers (57% vs. 49%).   
Tulsky et al.21 evaluated the effect of peer health advisors for homeless LTBI patients; 118 
participants were randomized to receive DOT with an incentive, DOT with peer support, or SAT.  
Completion was significantly higher among those given an incentive, and there was no 
difference between peer-assigned and SAT groups (44% vs. 19-26%).  Failure was attributed to 
poor training of peer advisors on TB prevention education. 
 
DISCUSSION 
This review critically analyzes all aspects of TLTBI adherence, from published adherence rates 
to TLTBI predictors, as well as adherence interventions that have been tested in diverse patient 
groups.  It was determined that TLTBI adherence and completion rates are suboptimal across 
high-risk groups, regardless of treatment regimen. TLTBI completion rates in the U.S. and 
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 Canada generally fall below established targets and have been reported to range from 20 to 65% 
for a 6-month course of self-administered treatment; a few smaller studies were able to achieve 
higher completion rates.  
Associations between patient factors, clinic facilities, or treatment characteristics and adherence 
to LTBI treatment were found to be inconsistent across studies.  Adherence does not appear to be 
related to patients’ age, gender, place of birth, or race.  In the few instances of a significant 
association, studies exhibit inconsistent results.  Recent exposure to TB, marriage, social support, 
and higher education have been positively associated with LTBI treatment adherence. 
Conversely, injection drug use, alcohol abuse, lack of health insurance, unemployment, prior 
BCG vaccination, and recent hospitalization have been associated with failure to complete.  
Homelessness has been found to be a mixed predictor, sometimes demonstrating a positive 
association and sometimes a negative one. Patients’ concerns about drug toxicity and side effects 
have been associated with lower treatment completion as has onset of clinical symptoms.  
Concurrent methadone treatment has been associated with better completion or lower 
completion.  Shorter courses of TLTBI, including combinations of RIF, PZA, rifabutin and/or 
INH, have been associated with improved adherence.   
Adherence interventions have been developed to improve TLTBI adherence in the U.S. and 
Canada; however, no single intervention has shown consistent effectiveness.  Incentives, 
contextual considerations, and professional adherence counseling were successfully applied to 
improve adherence, but they need to be tested for reliability in diverse settings.  Interventions 
using DOT, education programs, and peer support report mixed findings and warrant further 
exploration in the context of TLTBI. 
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 This review represents the first attempt to synthesize, integrate, and critically analyze all facets 
of adherence to TLTBI in the U.S. and Canada including adherence measurement, treatment 
completion rates, predictors for adherence, and adherence interventions that have been tested in 
diverse patient groups.  The two reviews previously published on TLTBI adherence differ 
considerably in scope and breadth from this review.  An earlier review compared LTBI treatment 
outcomes among HIV-infected patients in the U.S.4  The objective of the review was to 
determine the effectiveness of LTBI treatment in reducing the risk of active tuberculosis and 
death in persons infected with HIV.  The authors concluded that treatment of LTBI reduces the 
risk of active tuberculosis in HIV positive individuals with a positive tuberculin skin test.  A 
more recent review examined DOT intervention outcomes for LTBI and TB disease 
worldwide.102  The authors concluded that while the DOT strategy includes a number of useful 
components, the available evidence does not provide strong support for the routine adoption of 
direct observation in favor of self administration of treatment either for people with active 
tuberculosis or those with latent tuberculosis.  In addition, they found no evidence that one form 
of direct observation is better than the other, i.e., outcomes from clinic-based DOT and 
community-based DOT were similar as were outcomes for DOT provided by a family member or 
a community health worker.102   
This review has some limitations.  First, it is limited to evaluating outcomes within adult 
populations.  Studies with adolescents and children were not included in this review because they 
face significantly different issues in the context of treatment adherence, particularly with parental 
involvement in adherence.  Second, the review focuses on studies published in the U.S. and 
Canada, in order to represent countries with resources to routinely treat LTBI.  Thus the impact 
and relevance of this review is expected to be most applicable to these regions.  Third, the 
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 findings are tempered by methodological limitations of the reviewed studies; most notably the 
lack of a gold standard to reliably and accurately measure TLTBI adherence.  However, every 
attempt was made to fully describe the advantages and limitations of each measurement method.  
Finally, many studies were not designed specifically to assess treatment completion but rather to 
assess program outcomes or medication safety.  Therefore, treatment completion calculations 
varied across reviewed studies.  More reliable and comparable comparisons were made by 
calculating completion rates as the number completing therapy over those initiating therapy.   
 
CONCLUSION  
If the goal of TB elimination is to be realized, LTBI must be effectively treated.  In 2002, an 
estimated 291,000-433,000 individuals were treated for LTBI in the U.S., preventing 4,000-
11,000 TB cases.105 Consistently employing tools for measuring and improving adherence are 
fundamental.  Understanding and educating patients, and identifying barriers to treatment 
adherence will facilitate the development of more effective and appropriate interventions.  Our 
review shows the need for further large-scale studies in TLTBI adherence.  In addition to 
providing important background for research, our findings may help guide program planning and 
practice in individual clinics and jurisdictional TB control programs.  A ‘one-size-fits-all’ 
approach to TLTBI adherence is not likely to succeed across all settings.  Innovative approaches 
can inspire future interventions and suggest solutions for the current problems facing some LTBI 
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 Table 1 Comparison of disease- and treatment-related factors affecting treatment adherence in 









Strong Weak Hinders 
Perceived susceptibility 
 
Strong Weak Hinders 
Perceived accuracy of 
diagnosis 
 
Strong Weak Hinders 
Duration of therapy 
 
Usually 6 months Usually 9 months1 Similar to TB disease 







Directly observed therapy 
 
Standard of care Not standard of care Hinders 
Symptoms 
 
Symptomatic Asymptomatic Hinders 
Infectiousness 
 
Infectious Non-infectious Hinders 
Toxicity concerns 
 
Strong Strong Similar to TB disease 
Public health threat 
 
Threat Indirect threat Hinders 
1 LTBI treatment was traditionally with 6INH or 12INH depending on HIV status but with the 2000 LTBI treatment 
guidelines, it is now either a course of 6INH or 9INH, regardless of HIV status.   




 Table 2 Study inclusion/exclusion criteria 
 
Study inclusion criteria 
 
Study exclusion criteria 
- Quantitative studies 
- Peer-reviewed articles 
- From 1/1/1997 to 12/31/2007 
- Adult populations 
- U.S. and Canada 
- English language 
 
- Qualitative studies 
- Meta-analyses or reviews 


















Ensures dose intake  
Serves as an adherence 
intervention 
Expensive 
Time and labor intensive 
May be impractical 
May be perceived as paternalistic or 
intrusive 
 
Batki et al., 200211; Bock 
et al., 200123; Chaisson et 
al., 200224; Gourevitch et 
al., 199912; Heal et al., 
199813; Kim et al., 200329; 
Lobato et al., 200378; 
Lobato et al., 200514; 
Lorvick et al., 199915; 
Malotte et al., 200116; 
McNab et al., 200026; 
Narita et al., 200227; 
Nolan et al., 199730; 
Nyamathi et al., 200617; 
O’Connor et al., 199918; 
Priest et al., 200425; 
Scholten et al., 200319; 
Snyder et al., 199931; 
Stout et al., 200328; 
Tulsky et al., 200021; 
Tulsky et al., 200420; 





May be impractical 
May reflect recent dose intake only 
Subject to individual 
pharmacokinetic variations 
Subject to drug/food interactions 
Unsuitable for multiple drug 
regimens 
 
Chaisson et al., 200133; 
Dubanoski et al., 199834; 
Mangura et al., 199735 
 
Clinic attendance Cost-effective 
Practical 
Poor attendance may 
help identify poor 
adherence 
 
Does not ensure dose intake 
Good attendance may not reflect 
good adherence 
Ailinger et al., 200638; 
Batki et al., 200211; Bock 
et al., 199939; Dubanoski 
et al., 199834; Gilroy et al., 
200040; Lardizabal et al., 
200644; Lavigne et al., 
200641; Tulsky et al., 
200021; White et al., 
199843; White et al., 





Patient self-report Cost-effective 
Practical 
High specificity for non-
adherence  
Subjective 
Does not ensure dose intake 
Low sensitivity for non-adherence 
Subject to recall bias  (may only 
Ailinger et al., 199845; 
Bandyopadhyay et al., 
200246; Chaisson et al., 
200133; Cook et al., 
42






Limitations Use in TLTBI 
Helps identify reasons 
for non-adherence 
 
reflect short-term adherence) 
Subject to social desirability bias 
Subject to overestimation 
 
200649; Dubanoski et al., 
199834; Goldberg et al., 
200447; Gordin et al., 
199792; Heal et al., 199813; 
Lavigne et al., 200641; Lee 
et al., 200250; Levesque et 
al., 200451; LoBue et al., 
200348; McNeill et al., 
200352; Sackoff et al., 








Does not ensure dose intake 
Low sensitivity and low specificity 
for non-adherence 
Subject to overestimation 
 





Helps reflect long-term 
adherence 
Easily implemented in 
clinical settings 
Expensive 
May be impractical or inconvenient 
Does not ensure dose intake 
Subject to underestimation (due to 
decanting or pocket dosing) 
Subject to malfunctioning 
Interferes with pillbox use 
Unsuitable for multiple drug 
regimens 
 
Chaisson et al., 200133; 
Menzies et al., 200456; 
Menzies et al., 200555  
Pill count Objective 
Cost-effective 
 
Does not ensure dose intake 
Subject to pill dumping 
Subject to overestimation 
Difficult to implement in clinic 
settings 
 
Bandyopadhyay et al., 
200246; Brassard et al., 
200457; Chaisson et al., 
200133; Dubanoski et al., 
199834; Heal et al., 199813; 
Lardizabal et al., 200644; 
Lavigne et al., 200641; 
Mangura et al., 199735; 






Practical if patients 
access one pharmacy or 
clinic 
 
Does not ensure dose intake 
May be impractical if patients 




Batki et al., 200211; 
Lardizabal et al., 200644; 
LoBue et al., 200348; 
Narita et al., 200227; 
Parsyan et al., 2007; Shieh 
et al., 200659; Shukla et 
al., 200260; Stout et al., 
200328; Tavitian et al., 
200361; Tulsky et al., 


















May help counter the 
limitations of individual 
methods  
 
May be time and labor intensive 
Difficult to implement in clinical 
settings 
 
Chaisson et al., 200133; 
Dubanoski et al., 199834; 
Heal et al., 199813; 
Lardizabal et al., 200644; 
Lavigne et al., 200641; 
LoBue et al., 200348; 
Mangura et al., 199735; 
McNab et al., 200026; 







May help counter the 
limitations of individual 
methods 
May be time and labor intensive 
Difficult to implement in clinical 
settings 
Conditional on the validity of 
individual methods 
 
Dubanoski et al., 199834 


















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Table 5 Predictors of adherence to LTBI medications 
 








 >65 years old 
 <35 years old 
 Increasing age 
 
Bock et al., 199939 
Lobue and Moser, 200348 
Priest et al., 200425 








Lavigne et al., 200641 
Lobue and Moser, 200348 
Lobato et al., 200514 





Lobue and Moser, 200348 
 
Place of birth 
Foreign-born 
 
New immigrants (<5 years) 
Haiti or Dominican Republic 
 
Bock et al., 199939 






White et al., 200577 
Parsyan et al., 200758 
 
Patient-related factors 
Recent exposure to TB Reichler et al., 200264  
Higher education White et al., 200577 
Nyamathi et al., 200617 
 
Substance use 
 Injection drug use 
 Excessive alcohol use 
 Daily alcohol/drug use 
 Alcohol use by men 
  
Lobato et al., 200514 
Lobue and Moser, 200348 
Nyamathi et al., 200617 
Gilroy et al., 2000 
Living conditions 
 Homelessness 
 Stable housing 
 
Nyamathi et al., 200617 
Tulsky et al., 200420 
Tulsky et al., 200021 
White et al., 200242 
 
Lobue and Moser, 200348 
Marital status  Nyamathi et al., 200617 
Health insurance Nyamathi et al., 200617  
Unemployment  Lardizabal et al., 200644 
Lobato et al., 200514 
Prior BCG vaccination  Shukla et al., 200260 
Recent hospitalization  Nyamathi et al., 200617 
Importance of treatment completion Nyamathi et al., 200617  
Intention to adhere Nyamathi et al., 200617  
Low perceived risk of active disease  Shieh et al., 200659 
Social support Nyamathi et al., 200617  
 





 Table 5 Predictors of adherence to LTBI medications 
 






Concerns about medication toxicity and side effects  Lobue and Moser, 
200348 
Ailinger and Dear, 
199845 
Development of clinical symptoms  Shukla et al., 200260 
Priest et al., 200425 
Fear of venipuncture  Shieh et al., 200659 
Concurrent methadone treatment Batki et al., 200211 Mangura et al., 199735 
Concomitant medication use by women  Gilroy et al., 200040 
 























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































 Chapter 3: 
The Changing Face of Latent Tuberculosis Infection in Harlem, New York: 







INTRODUCTION: Poor adherence to LTBI treatment and corresponding modest treatment 
completion rates impede efforts to eliminate TB in this country.  While community-level social 
demographic characteristics are thought to influence adherence, few studies have examined 
epidemiological changes over time in relationship to adherence patterns.  This issue is 
particularly critical in communities like Harlem, where TB rates have remained above national 
averages despite significant population changes. 
OBJECTIVE: To describe the change in demographic, social, and behavioral characteristics of 
patients undergoing treatment for LTBI in the Chest Clinic at Harlem Hospital between 1996 and 
2005.  
METHODS: A cross-sectional examination of baseline data from participants in two sequential 
randomized controlled trials.  Demographic, social, and behavioral characteristic data are 
summarized using basic descriptive statistics (means, medians, proportions) in two distinct time 
points: participants recruited between 1996 and 2000, and participants recruited between 2002 
and 2005.  Differences and similarities between Study A and Study B participants were 
investigated using student’s t-tests, Pearson’s χ2 tests, and Fisher’s exact tests.   
RESULTS: Of the 610 participants enrolled across both studies, 360 were recruited into Study A 
and 250 into Study B.  Average age of participants in both studies was similar (39 vs. 40, 
p=0.498).  Substantially more participants in Study B were male (70% vs. 58%, p=0.002) and 
many more were Africans (36% vs. 9%, p<0.001).  Substantially more of the Study B 
participants were married (39% vs. 26%, p=0.001), and more were foreign-born (67% vs. 48%, 
p<0.001), with less experience of prior LTBI treatment (6% vs. 14%, p=0.003).  There was 
substantially less current homelessness (16% vs. 26%, p=0.005) and unemployment (59% vs. 
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 73%, p<0.001) in Study B than in the Study A.  Overall, close to half of all participants enrolled 
in the studies were current smokers, about a third consumed alcohol and 20% used drugs at the 
time of enrollment.  There is evidence of a trend in changes in drug use, with fewer Study B 
participants ever (52% vs. 59%, p=0.086) or currently (16% vs. 22%, p=0.057) using drugs. 
CONCLUSIONS: The cohort of participants receiving treatment for LTBI in Harlem between 
2002 and 2005 tend to have higher levels of foreign-birth and marriage, and lower levels of 
homelessness and unemployment, less experience with prior LTBI treatment, and lower rates of 
smoking and drug use than patients in the late 1990s.  The 2002-2005 participants undergoing 
treatment for LTBI mirror the NYC and national TB picture in terms of gender, age, and foreign 
birth; however, the racial distribution is different as the Harlem community does not have a large 
population of Asians. 
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 INTRODUCTION 
An estimated 9 to 14 million persons in the United States have latent tuberculosis infection 
(LTBI) and are therefore at risk for progression to active disease.1  Treatment for latent 
tuberculosis infection (TLTBI) has been identified by the Centers for Disease Control and 
Prevention (CDC), the Advisory Council for the Elimination of Tuberculosis, the American 
Thoracic Society, and the Institute of Medicine of the National Academy of Sciences as one of 
the major strategies for elimination of tuberculosis (TB) in the U.S.2,3  However, LTBI treatment 
completion rates in the U.S. generally fall below established targets.4,5  Poor adherence to LTBI 
treatment and corresponding modest treatment completion rates impede efforts to eliminate TB 
in this country.  While community-level social demographic characteristics are thought to 
influence adherence, few studies have examined epidemiological changes over time in 
relationship to adherence patterns.   
This issue is particularly critical in communities like Harlem that were especially affected by the 
resurgence of TB in the early 1990s.  The TB case rate in Central Harlem rose to a high of 
240.2/100,000 in 1992,6 a rate comparable to those found in developing countries.  The TB 
control efforts implemented in NYC have resulted in the gradual decrease in TB case rates in 
Harlem to 16.7/100,000 in 2008.  Despite this decline, the TB case rate in Harlem is still four 
times the U.S. case rate (4.2/100,000) and more than 50% higher than the NYC rate (10.8 
cases/100,000).7  People of color in NYC have markedly higher rates of TB than whites with 
54% of cases occurring among blacks and Hispanics.7  With TB rates greatly exceeding the 
national average and the concomitant HIV epidemic, the Harlem community is vulnerable to TB.  
HIV infection is the most potent risk factor for development of TB, resulting in a 100-fold 
increase in risk in HIV-infected individuals compared to those without HIV infection.8-10  Other 
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 risk factors for development of TB include recent immigration, recent conversion of the TB skin 
test, homelessness, incarceration, and congregate settings.  
Historically, Harlem has been a center of African-American culture and a more recent home to 
many Latino immigrants.  Two thirds of the Harlem residents are African-American and 20% are 
Hispanic compared with the national average of 12% and 13% respectively.  It is among the 
most underprivileged areas in New York City, with approximately one-third of the population 
living in poverty compared with 21% in NYC and 12% nationally.  In addition, the 
unemployment rate is 9.8% in Harlem vs. 5.5% in NYC and 3.7% nationally.11  The community 
suffers from a large variety of socio-economic problems including homelessness and drug and 
alcohol use.  This is also a neighborhood whose population is at an elevated risk for HIV with 
prevalence rates double that of NYC as a whole (127.1/100,000 vs. 45.8/100,000 HIV 
diagnoses.12  Moreover, a recent surge of immigration into the neighborhood has brought new 
health challenges.  The majority of African immigrants living in Harlem come from West 
African countries in which HIV infection rates range from 2 to 7% and TB is endemic.  In 2003, 
African immigrants accounted for 9.3% of new TB cases in New York City, although they make 
up less than 1% of the population.13  Because of crowded housing and other health conditions, 
immigrants may be at an elevated risk for developing active TB disease, particularly if also HIV-
infected.  At the same time, these recently arrived members of the community and its traditional 
African-American population share multiple barriers to health care and lack knowledge about 
disease prevention strategies, which can exacerbate existing health care disparities in Harlem.  
The social stigma attached to many infectious diseases gives rise to fears of discrimination and 
isolation, and often inhibits people from seeking testing and treatment services.  Another 
significant barrier in this population is fragile and inadequate social support for medication 
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 within existing social networks.14,15  The population that is eligible for treatment for LTBI in 
Harlem includes predominantly minorities and a large proportion of recent immigrants, women, 
and substance users.   
The objective of this analysis was to describe the change in characteristics of patients undergoing 
treatment for LTBI in the Chest Clinic at Harlem Hospital between 1996 and 2005.  
 
STUDY POPULATION AND METHODS 
Setting and Study Population 
Located in Central Harlem, New York City, Harlem Hospital Center is a publicly funded hospital 
that serves as the primary source of care for many people residing in Northern Manhattan.  The 
hospital’s Chest Clinic provides services to patients with TB and with LTBI.  Of the patients 
with TB enrolled in the Harlem Hospital Directly Observed Therapy (DOT) program at the time 
of these studies, approximately one third were foreign-born and many indicated that English is 
not their primary language.  The Chest Clinic serves a predominantly disadvantaged population 
with a large proportion of the patients receiving public assistance, large numbers of immigrants, 
and high rates of unemployment, homelessness and substance abuse.  Many of the patients are 
referred to the clinic by homeless shelters, substance abuse programs and community based 
organizations where TB skin testing is often required for residency or for services like English 
language classes. 
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 Between 1996 and 2000 and between 2002 and 2005, patients who initiated treatment for LTBI 
were recruited from the Harlem Hospital Chest Clinic in New York City into two randomized 
controlled trials assessing the effect of an experimental intervention.  Providers in the TB Clinic 
used the prevailing CDC/ATS guidelines to determine candidacy for treatment of LTBI.  Patients 
with the following characteristics were eligible for the study: recommended for initiation of a 
CDC recommended drug regimen for treatment of LTBI; age of 18 years or older; and able and 
willing to sign consent form.  Patients with the following characteristics were excluded: 
receiving DOT for LTBI; or had evidence of active TB disease.  All decisions about starting or 
stopping treatment for LTBI were made by providers in the Chest Clinic and were based on 
standard CDC criteria.   
Patients who fulfilled these criteria were referred for study participation.  Potential study 
candidates were provided with further information regarding the study and invited to participate. 
All participants signed a consent form approved by the Columbia University Institutional Review 
Board at Harlem Hospital.  Following a baseline interview with a research assistant, participants 
were randomly assigned to either the intervention or control group. 
The first study, Pathways to Completion, recruited patients from the Chest Clinic between 1996 
and 2000.  The second Study, Tuberculosis Adherence Partnership Alliance Study (TAPAS), 
recruited patients between 2002 and 2005.  Both studies had a low refusal rate.  Demographic 
characteristics of study participants did not differ significantly from those of the clinic 
population.     
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 Participant Interviews 
Structured questionnaires were developed and pilot-tested prior to each study to ensure clarity 
and precision of the instruments.  Research assistants, who received training for the studies, 
conducted the interviews in English, French, and Spanish.  Completed interviews were reviewed 
by the study coordinators for completeness.   
Interviewers collected detailed demographic, social, and behavioral information including: place 
of birth, history of homelessness, patterns of substance use, employment, marital status, and prior 
LTBI treatment.  Knowledge of TB transmission, treatment, and diagnosis was assessed using 
true/false questions.  Agreement with attitudes regarding LTBI was measured on a 4-point Likert 
scale where 1 indicates “strongly disagree”, 2 is “disagree”, 3 is “agree”, and 4 is “strongly 
agree.”   
Data Analysis 
Pearson’s χ2 test, or Fisher’s exact test where appropriate, was used for comparisons of 
categorical variables.  Student’s t-test was conducted for comparisons of continuous variables.  
The two studies had a different number of knowledge items; however, a summary knowledge 
score for six items that were the same across the two studies was constructed by calculating the 
sum of correct answers to knowledge items.  Statistical analyses were performed using SPSS 





Of the total 610 participants, 360 were recruited into the Pathways study (Study A) and 250 into 
the TAPAS study (Study B).  Overall, 63% were male, 51% were African-American, 20% were 
African, 21% Latino, and 55% were less than 40 years old.  Slightly more than half of the 
participants were foreign-born, 22% reported current homelessness, 67% were unemployed, 57% 
had completed high school, and 31% were married (Table 1). 
The average age of participants in both studies was similar (39 vs. 40, p=0.498).  Substantially 
more participants in Study B were male (70% vs. 58%, p=0.002) and many more were Africans 
(36% vs. 9%, p<0.001).  Substantially more of the Study B participants were married (39% vs. 
26%, p=0.001), and more were foreign-born (67% vs. 48%, p<0.001), with less experience with 
prior LTBI treatment (6% vs. 14%, p=0.003).  There was substantially less current homelessness 
(16% vs. 26%, p=0.005) and unemployment (59% vs. 73%, p<0.001) in Study B than in the 
Study A.  
Overall, close to half of all participants enrolled in the studies were current smokers, about a 
third drank alcohol and 20% used drugs at the time of enrollment.  There is a possible trend in 
changes in drug use, with fewer Study B participants ever (52% vs. 59%, p=0.086) or currently 
(16% vs. 22%, p=0.057) using drugs. 
Knowledge of TB transmission, diagnosis and treatment at baseline was 4.14 out of a possible 
6.0 in all participants; Study A participants had a better knowledge score (4.27 vs. 3.94, 
p<0.001).  Overall, participants agreed with the statement, “you believe that you have the TB 
germ” (mean=3.06), “taking TB medications is important” (mean=3.88), and “you care about 
what your family and friends think of your TB treatment” (mean=2.77); participants disagreed 
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 overall with the statements, “going to appointments is more trouble than it is worth” 
(mean=1.37) and “as hard as you try, you are going to miss some of your medicines” 
(mean=1.91).  No significant differences were noted between the two studies on the prior 
attitudinal items but some differences between the studies were noted in the following attitudinal 
items.  All participants agreed that “TB is a disease you have to take seriously” but the 
agreement was stronger among Study A participants (3.90 vs. 3.76, p<0.001).  Stigma as 
measured by agreement with “you are embarrassed to tell you have TB” was stronger among 
Study A participants (2.52 vs. 2.23, p=0.003).  While overall participants strongly disagreed with 
the statements “you know better than the doctor when it is time to stop taking your medications” 
and “TB medications are a hassle,” the disagreement was less strong among Study B participants 
(1.23 vs. 1.59, p<0.001; 1.34 vs. 1.60, p<0.001 respectively).  There was general agreement with 
the statements “no matter what you do, you can get TB” and “if you do the right thing, you can 
avoid getting TB”; however, Study A participants more strongly agreed with the prior (3.08 vs. 
2.52, p<0.001) and Study B participants more strongly agreed with the latter (3.10 vs. 3.37, 
p0.003).  There was stronger agreement among Study A participants that “it takes something bad 
to not take the TB medicines” (3.15 vs. 2.57, p<0.001).   
 
DISCUSSION 
There are higher proportions of foreign-born, married, employed African participants receiving 
treatment for LTBI in Harlem between 2002 and 2005 than in the late 1990s.  Current Harlem 
participants undergoing treatment for LTBI mirror the NYC and national TB picture in terms of 
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 gender, age, and foreign birth; however, the racial distribution is different as the Harlem 
community does not have a large population of Asians.7  
Participants in the 2002-2005 cohort tend to have lower knowledge levels regarding TB 
diagnosis and treatment than past participants.  Participants’ attitudes were fairly positive with 
participants believing that they have the TB germ, acknowledging that TB is serious disease and 
taking TB medications is important, and that doing the right thing may help them avoid TB.  
Furthermore, negative attitudes regarding the doctor’s knowledge of treatment or the hassle 
involved in the taking the medications were not very strong, though Study A participants were 
more dismissive of these notions.  Stigma appears less strong in the more recent study population 
(Study B) possibly as more participants are from areas where TB is endemic.   
Limitations 
This analysis has several limitations.  Patients receiving DOT for LTBI were excluded from the 
study; however, the DOT for LTBI population was found to be similar to the study population of 
Pathways16 and no changes in procedures for DOT referrals were implemented in the clinic 
during that period.  When comparing the two clinic populations, we could only evaluate 
questions that were comparable across the two studies.  The TB knowledge and attitudes sections 
were different across the studies, which limited the number of items that could be compared.  
However, a reasonable number of attitudinal items were comparable and this did not affect the 
analysis in terms of demographic characteristics and lifestyle factors as the two studies had very 
detailed sections that were comparable.  This analysis examines changes in study populations, 
which may differ from the Harlem clinic population in general.   Additionally, this analysis looks 
at the change in clinic populations in only one clinic in one city and the findings may not be 
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 generalizable to other populations.  However, while this clinic population may be different than 
other parts of the country in terms of origin of immigrants, we believe that this clinic is fairly 
representative of inner city urban populations, which tend to include relatively higher 
proportions of immigrants and disadvantaged persons.  Moreover, this analysis is not limited to a 
specific high risk group but instead to a general clinic population, albeit one at high risk of 
developing TB disease.   
 
CONCLUSION 
Participants receiving treatment for LTBI in Harlem from 2002-2005 tend to have higher levels 
of foreign-birth and marriage, and lower levels of homelessness and unemployment, less 
experience of prior LTBI treatment, and lower rates of smoking and drug use than participants in 
the late 1990s.  The 2002-2005 cohort of Harlem participants undergoing treatment for LTBI 
mirror the NYC and national TB picture in terms of gender, age, and foreign birth; however, the 
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 Table 1: Clinic Baseline Patient Characteristics by Study 







 N % N % N % χ2 p-value 
Male  386 63.3 210 58.3 176 70.4 9.245 0.002 








































Ever homeless 221 36.3 138 38.3 83 33.3 1.592 0.207 
Homeless past yr 132 21.7 92 25.6 40 16.1 7.910 0.005 
Married/Common-law 190 31.2 93 25.9 97 38.8 11.416 0.001 
Foreign-born 339 55.6 172 47.8 167 66.8 21.623 <0.001 
Completed high school 336 56.9 183 53.8 153 61.2 3.197 0.074 
Unemployed 409 67.0 262 72.8 147 58.8 13.048 <0.001 
Prior LTBI treatment 64 10.5 49 13.6 15 6.0 8.917 0.003 
Emotional/psych 
hospitalizations 
42 6.9 28 7.8 14 5.6 1.149 0.284 
Currently smoke 254 41.6 170 47.2 84 33.6 11.266 0.001 
Ever drink alcohol 427 70.9 248 70.5 179 71.6 0.093 0.760 
Currently drink alcohol 197 32.3 117 32.5 80 32.0 0.017 0.897 
Ever drug use 340 55.7 211 58.6 129 51.6 2.940 0.086 




 Table 2: Participants Knowledge and Attitudes by Study 
 







 Mean s.d. Mean s.d. Mean s.d. T p-value 
Knowledge score 4.14 0.998 4.27 0.988 3.94 0.982 4.088 <0.001 
TB is disease you have to 
take seriously 
3.84 0.452 3.90 0.446 3.76 0.448 3.841 <0.001 
No matter what you do, 
can get TB 
2.86 1.186 3.08 1.136 2.52 1.184 5.864 <0.001 
Taking TB medications is 
important 
3.88 0.452 3.88 0.452 3.88 0.452 -0.014 0.989 
Know better than doctor 
when best to stop 
medications 
1.37 0.845 1.23 0.685 1.59 1.003 -5.014 <0.001 
Going to appointments 
more trouble than worth 
1.37 0.764 1.32 0.755 1.44 0.775 -1.822 0.069 
If do the right thing, can 
avoid getting TB 
3.21 1.135 3.10 1.205 3.37 1.004 -2.994 0.003 
Embarrassed to tell you 
have TB 
2.41 1.263 2.52 1.302 2.23 1.183 2.956 0.003 
Believe that you have the 
TB germ 
3.06 1.154 3.06 1.189 3.06 1.101 0.079 0.937 
Care what family/friends 
think of TB treatment 
2.77 1.237 2.82 1.257 2.71 1.204 1.091 0.276 
As hard as you try, you are 
going to miss some of your 
medicines 
1.91 1.085 1.86 1.124 1.99 1.020 -1.499 0.134 
TB medications are a 
hassle 
1.44 0.848 1.34 0.799 1.60 0.897 -3.636 <0.001 
Takes something bad to 
not take meds 
2.92 1.284 3.15 1.247 2.57 1.263 5.677 <0.001 
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Predictors of Latent Tuberculosis Infection Treatment Completion in the U.S.: 




This chapter has been published as: 
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Tuberculosis Infection Treatment Completion in the U.S.: an Inner City Experience. Int J TB & 




RATIONALE: Few studies have examined predictors of latent TB infection (LTBI) treatment 
completion in inner city urban populations in the U.S. 
OBJECTIVE:  To assess LTBI treatment completion rates and predictors in an urban clinic 
cohort.  
METHODS:  Data from control groups of two sequentially-conducted randomized controlled 
trials of LTBI treatment were analyzed for treatment completion rates.  Participants in Study A 
(n=183), conducted in 1996-1999, self-administered daily INH for 6-12 months while 
participants in Study B (n=122), conducted in 2002-2005, self-administered daily INH for 9 
months.   
RESULTS:  Overall, 45.9% of participants completed therapy, with significantly higher completion 
rates in Study B than Study A (38.7% vs. 56.6%, p=0.0027).  Marriage and alcohol use were significant 
predictors of completion (ARR=1.480, 95% CI 1.174-1.865) and non-completion (ARR=0.740, 95% CI 
0.585-0.935) respectively; multivariate analysis indicated increased completion among married persons 
of foreign-birth and among alcohol users who were homeless.  TB knowledge and attitudes were not 
significant predictors.    
CONCLUSIONS:  The design provided an opportunity to assess predictors of LTBI treatment 
completion in this inner city population.  Social circumstances were the strongest predictors of 
treatment completion, suggesting that tangible social services may be more effective than 
educational programs in encouraging treatment completion. 
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 INTRODUCTION 
An estimated 9-14 million persons in the U.S. have latent tuberculosis infection (LTBI) and are 
therefore at risk for progression to active tuberculosis (TB) disease.1  Diagnosis and treatment of 
LTBI has been identified by the Centers for Disease Control and Prevention and the Institute of 
Medicine as a major strategy for elimination of TB in the U.S.2,3  Approximately 200-300,000 
individuals are treated for LTBI in the U.S. annually, with reported LTBI treatment completion 
rates in the U.S. ranging from 20-65% for a 6-month course of self-administered treatment; while 
some studies found higher completion rates.4  In a national survey, Horsburgh reported 47% 
completion among patients treated in 2002.5  Better understanding of factors associated with 
LTBI treatment completion rates is essential to efforts to eliminate TB in this country.   
The challenge of LTBI treatment is particularly critical in inner city urban neighborhoods like 
New York City’s Central Harlem, where rates of TB greatly exceed the national average 
(16.7/100,000 vs. 4.2.4/100,000 in 2008, respectively)6 and elevated rates of HIV infection 
increase the population vulnerable to TB.  Harlem has long been a predominantly African-
American community and is home to a growing African immigrant population.  Potential barriers 
to medication adherence in Harlem include poverty, drug and alcohol use, homelessness, fragile 
or inadequate social support networks, low awareness of available low-cost or free health care 
services, and a dearth of culturally appropriate health care.  TB-related social stigma, which 
gives rise to fears of discrimination and isolation, may also impede acceptance and completion of 
LTBI treatment.   
Few studies have examined predictors of adherence and completion of LTBI treatment and the 
few that have been conducted in inner city urban populations have focused on selected 
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 demographic groups7-11 rather than broader clinic populations.12-15  Additionally, few prior 
studies have given significant attention to TB attitudes. 
The objectives of this study were to assess LTBI treatment completion rates and predictors of 
completion, including TB knowledge and attitudes, among an inner-city urban cohort.  Foreign 
birth, homelessness, and current substance use were hypothesized a priori to be risk factors for 
LTBI treatment non-completion.   
 
STUDY POPULATION AND METHODS 
Design, setting and sample 
This analysis used data from the control arms of two sequential randomized controlled trials 
evaluating a supportive intervention for LTBI treatment.  In 1996-1999 (Study A) and 2002-2005 
(Study B), all patients >18 years from the Harlem Hospital Chest Clinic diagnosed with LTBI 
following CDC guidelines2 were approached for participation using identical inclusion and 
exclusion criteria.  Both studies were approved by the Columbia University Institutional Review 
Board at Harlem Hospital.   
Providers blinded to study status made clinical determination of LTBI treatment completion/non-
completion according to CDC guidelines; these data were subsequently abstracted from medical 
charts by research staff.  Datasets from both studies were combined to increase the power for this 
analysis.  Treatment completion and predictor variables were measured identically in both 
studies.  A variable indicating study of origin was used to adjust for differences between studies.     
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 The studies differed in the use of electronic monitoring devices (EMDs), which recorded opening 
times of medication bottles in Study B but not Study A.  Furthermore, Study A participants were 
prescribed 6-12 months of isoniazid (depending on HIV status), while Study B patients received 9 
months of isoniazid.   
Instruments 
Trained research assistants conducted face-to-face interviews using structured questionnaires on 
demographics, homelessness (street vs. shelter not distinguished), substance use, life stressors, 
and TB-related knowledge and attitudes at enrollment.  Current substance use was defined as any 
alcohol or drug use in the past month.  TB knowledge items included six true/false questions on 
TB transmission, diagnosis, and treatment.  Twelve attitudinal items were measured on a four-point 
Likert scale ranging from ‘strongly disagree’ to ‘strongly agree’.   
Data Analysis 
Student’s t-test was used to compare continuous variables, while χ2 or Fisher’s exact test was used 
to assess association for categorical variables.  Binomial regression was used to evaluate predictors 
while adjusting for study of origin.  Variables significant at <0.10 and variables hypothesized a 
priori to be predictors were candidates for the final multivariate regression model, which was 
constructed based on a manual, stepwise assessment of predictors and interactions.  Model 
diagnostics were computed for final models and assessed using the Hosmer and Lemeshow 
Goodness-of-Fit Test, along with Akaike’s Information Criteria (AIC) and Schwartz’s Information 
Criterion (SIC).16-18  A summary knowledge score was constructed by calculating the proportion 
of correct answers to knowledge items.  Factor analysis was used to develop scale scores for 
attitudes; scales were produced by taking mean scores for all attitudinal items in a specific factor.  
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 Internal consistency and reliability of scales was tested with Cronbach’s alpha, using threshold of  
>0.6.19  Attitudinal items were analyzed using the ordinal four-point scale where the response 
patterns appeared to fit a logistic curve, or categories were collapsed to dichotomous outcomes.  
Statistical analyses were performed using SAS (version 9.1.3, 2000; SAS Institute Inc, Cary, NC) 




Table 1 describes the study population, shown by study of origin (Study B vs. Study A).  Overall, 
participants were more likely to be male (63.9%), African-American or Latino (72.2%), <40 years 
old (55.1%), unemployed (68.5%), and not married (70.2%).  The majority of participants were 
foreign-born (52.5%), while substantial proportions reported homelessness (25.6%) or substance 
use (22.6%) at enrollment.  There were significant differences between participants in Studies A and 
B, with the latter more likely to be male, African, foreign-born, employed, married, and on a nine-
month regimen, but less likely to be homeless or report drug use. 
LTBI Treatment Completion Rates 
Overall, 45.9% of participants completed therapy, with a significantly higher completion rate 
among Study B participants (56.6%) than Study A participants (38.7%) (p = 0.0027).  A higher 
completion rate was observed in Study B for every demographic subgroup investigated (Table 2). 
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 Age, marriage, current homelessness, and ever having used alcohol were associated with treatment 
completion, either in the combined sample (age, marriage, homelessness, lifetime alcohol use) or in 
Study B population (age, marriage).  Place of birth, employment, and race/ethnicity showed 
significant differences for treatment completion in the combined sample but not in either individual 
study.  Furthermore, the effect of race/ethnicity is inconsistent in the two studies; Latinos had higher 
completion than African-Americans in Study A but lower completion than African-Americans in 
Study B.  
Predictors of Treatment Completion 
Table 3 summarizes predictors of treatment completion, after controlling for study of origin.  
Lifetime alcohol use (ARR=0.740, 95% CI 0.585-0.935), age (ARR=0.784, 95% CI 0.619-0.993), 
and marriage (ARR=1.480, 95% CI 1.174-1.865) were the only strongly significant predictors, with 
homelessness (ARR=0.720, 95% CI 0.511-1.016), and more than 2 life stressors reported 
(ARR=0.807, 95% CI 0.638-1.021) meeting the 0.10 criterion for consideration in multivariate 
modeling.  Foreign birth (ARR=1.157, 95% CI 0.897-1.494) and current drug use (ARR=0.876, 
95% CI 0.635-1.207) were further considered in the multivariate models because they had been 
hypothesized a priori to be risk factors for non-completion of LTBI treatment.   
Table 4 presents a multivariate model for predicting treatment completion.  According to this 
model, foreign birth (ARR=0.709, 95% CI 0.501-1.001), marriage (ARR=0.520, 95% CI 0.239-
1.130), current homelessness (ARR=0.603, 95% CI 0.387-0.939), and current alcohol use 
(ARR=0.759, 95% CI 0.564-1.020) were risk factors for non-completion of LTBI treatment; 
however, all of these factors were modified by interaction terms.  Unmarried foreign-born TB 
patients were less likely than U.S.-born patients to complete treatment, while married foreign-born 
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 TB patients were substantially more likely than U.S.-born patients to complete therapy 
(ARR=3.603, 95% CI 1.558-8.330).  Similarly, homeless persons who did not use alcohol were 
significantly less likely than persons with stable living situations to complete therapy; however, 
homeless persons who did use alcohol were more likely to complete therapy (ARR=2.412, 95% CI 
1.234-4.716).  As seen in Table 2, completion rates in the two studies varied significantly and study 
of origin was a significant predictor of completion in the multivariate model (ARR=0.721, 95% CI 
0.571-0.909).  However, no interactions between potential predictors and study of origin were 
found.  Diagnostic statistics were used to assess the validity of the final model.  These diagnostic 
tests confirmed that the final model conforms to statistical assumptions for binomial regression.    
TB Knowledge and Attitudes 
Factor analysis of the 12 attitudinal items yielded four factors accounting for 53.2% of the total 
variation; final factor solution is not shown.  Four scales were created but none achieved reliability; 
therefore, the attitudinal data was analyzed using individual items. 
Attitudinal items A1-A5 were distributed normally and were therefore analyzed using the four-point 
scale.  For some of the attitudinal items (A6-A12), better (or worse) completion rates were observed 
in the two extreme categories (‘strongly disagree’ and ‘strongly agree’) than in the two middle 
categories (‘disagree’ and ‘agree’).  Neither collapsing a four point scale nor combining ‘strongly 
agree’ with ‘agree’ and ‘strongly disagree’ with ‘disagree’ was appropriate for these variables.  
Depending on the distribution, the category with most responses was either designated as the 
reference group or the two middle categories (‘agree’ and ‘disagree’) were collapsed and used that 
as the reference group. 
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 Table 5 shows the relationship of TB-related knowledge and attitudes with treatment completion, 
after controlling for study of origin.  No individual knowledge items, nor the overall knowledge 
score, were significantly associated with completion.  However, the attitudinal items ‘no matter 
what you do, you can get TB’ (A6), ‘you are embarrassed to tell you have TB’ (A7), ‘you believe 
you have the TB germ’ (A8), and ‘you care about what your family and friends may think of your 
TB’ (A9) were significantly associated with LTBI treatment completion with p < 0.10.   
These variables (A6, A7, A8, A9) were each tested in the multivariate model shown in Table 4.  
Only agreeing with the statements ‘you believe you have the TB germ’ (A8) (p=0.0151) and ‘you 
care about what your family and friends may think of your TB’ (A9) (p=0.0269) were significant 
risk factors after adjusting for demographic and other characteristics in the multivariate model.  The 
addition of these attitudinal items did not change the association of other predictors in the model 
shown in Table 4 with treatment completion and model fitting criteria (notably SIC) did not indicate 
that these variables substantially improved the model shown in Table 4.   
 
DISCUSSION 
Ensuring completion of LTBI treatment benefits both the treated individual and society in 
general by preventing cases of active, infectious disease. Thus, understanding adherence and 
developing interventions to support it are critical to public health policy.20,21  This U.S. inner city 
urban setting provides a valuable opportunity to examine predictors of adherence to LTBI 
treatment in a clinic population where patients are at increased risk of getting TB and face many 
barriers to completion of treatment.  
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 Our results suggest that foreign birth, homelessness, marriage, and alcohol or drug use all influence 
completion of LTBI treatment through complex interactions. Overall, married persons had better 
completion, but married foreign-born patients were substantially more likely to complete therapy 
than unmarried foreign-born patients.  Similarly, alcohol users were less likely to complete therapy, 
but homeless alcohol users were more likely to complete treatment than other homeless patients. 
The latter is probably an artifact of our clinic population, which includes patients from alcohol and 
substance abuse rehabilitation programs.  Residence in such programs may have a positive effect on 
treatment completion because patients may have had more supervision of medications and 
appointment keeping.  Race/ethnicity did not appear to be associated with treatment completion, 
although the differences between the two study populations made this difficult to assess. 
The few recent studies of LTBI treatment adherence have not found it to be related to age, sex, 
place of birth or race.  Where significant associations are found, studies exhibit inconsistent results.4  
An even smaller number of studies examined predictors of adherence and completion of LTBI 
treatment in inner city clinic populations.  Our finding of lower completion rates among homeless 
patients and current alcohol users agrees with results of Lobue et al. found in San Diego in a general 
TB clinic population.13  Regarding foreign birth, our study found higher completion among married 
foreign-born patients.  However, Parsyan et al. identified birth in Haiti or the Dominican Republic 
as a risk factor for non-completion in a Boston Public Health TB clinic,14 while Lobue et al.13 and 
Bock et al.12 found foreign birth to be associated with higher completion rates.   
No knowledge items and few attitudinal items were associated with likelihood of completing 
treatment. Only two (‘believe you have the TB germ’ and ‘care about what your family and friends 
may think of your TB’) were significant after adjusting for demographic, social, and other 
characteristics, and both resist meaningful interpretation. Specifically, respondents who either 
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 strongly agreed or strongly disagreed with these statements were less likely to complete therapy 
than those who moderately agreed or disagreed.  The implications of these results are not clear.   
Knowledge and attitudes may be less important than social factors in determining treatment 
completion.  If so, educational programs aimed at increasing knowledge and modifying attitudes 
may be less effective than tangible assistance in encouraging treatment completion.  That is, if 
unmarried persons or those in unstable living conditions have difficulty completing treatment, then 
outreach programs that address their needs may improve completion rates.  
The greatest difference in completion rates was between Study A and B participants.  Study B 
participants were observed to have higher completion rates than Study A participants regardless 
of race, ethnicity, gender, education level, age, place of birth, life stressors, alcohol or drug use, 
employment status, marital status, and stability of housing, despite the longer regimen for Study 
B participants.  A primary difference between the studies was the use of EMDs in Study B for 
monitoring treatment adherence, suggesting that EMDs may have influenced treatment 
completion. 
Recent work has shown the importance of shortened LTBI treatment regimens for ensuring 
treatment completion,4 with completion ranging from 71.6% to 91.4% with four months of 
rifampin.22  Further research would be required to determine whether factors found to predict 
completion would remain effective predictors among patients on shortened regimens 





Although both studies were conducted in the same clinic, the study population changed 
somewhat between the time frames for the two studies.  Other differences included treatment 
regimens and the use of EMDs in Study B.  While statistical adjustments were made for these 
differences, it would have been preferable to have identical populations and protocols.  Another 
possible limitation is that providers may not have been consistent in their determination of 
treatment completion; however, the small number of providers making this determination was 
blinded to study status.  Another possible limitation is that self-reporting of some items (e.g., 
alcohol or drug use) may have been subject to social desirability bias in face-to-face interviews; 
similarly, whether homeless participants were living in the street or in a shelter and possibly 
receiving services was not assessed and it was not possible to tease it out.  Patients receiving 
DOT for LTBI were excluded from the study; however, the DOT for LTBI population was found 
to be similar to the study population of Pathways23 and no changes in procedures for DOT 
referrals were implemented in the clinic during that period.  Finally, since this study was 
conducted in an inner city urban setting, the results cannot be rigorously generalized to the 
general U.S. population, although they have strong implications for similar populations. 
 
CONCLUSIONS 
In this study of LTBI treatment completion in an inner city urban population, homelessness, 
foreign birth, alcohol use, and marriage predicted success at completing LTBI treatment.  Special 
efforts to reach patient groups identified with these factors should improve completion rates.  
Currently, the primary intervention for improving LTBI adherence consists of educational 
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 programs to increase knowledge and modify attitudes.  Our findings suggest that tangible assistance 
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Treatment duration     
6 months 176 (57.9) 176 (96.2) 0 (0%) <0.001 
9 months 122 (39.8) 0 (0%) 122 (100%)  
12 months 7 (2.3) 7 (3.8) 0 (0%)  
Demographics     
Age group     
40+ 137 (44.9) 78 (42.6) 59 (48.4) 0.3237 
<40 168 (55.1) 105 (57.4) 63 (51.6)  
Gender      
 Female 110 (36.1) 76 (41.5) 34 (27.9) 0.0149 
 Male 195 (63.9) 107 (58.5) 88 (72.1)  
Race/Ethnicity     
 Black or African-American 157 (51.5) 120 (65.6) 37 (30.3) <0.0001 
 Latino 63 (20.7) 39 (21.3) 24 (19.7)  
 African 59 (19.3) 13 (7.1) 46 (37.7)  
 Other 26 (8.5) 11 (6.0) 15 (12.3)  
Place of birth     
 US-born 145 (47.5) 104 (56.8) 41 (33.6) <0.0001 
 Foreign-born 160 (52.5) 79 (43.2) 81 (66.4)  
     
Social Characteristics     
Education – completed high school     
 No 130 (44.1) 83 (48.0) 47 (38.5) 0.1073 
 Yes 165 (55.9) 90 (52.0) 75 (61.5)  
Employment     
 No 209 (68.5) 138 (75.4) 71 (58.2) 0.0015 
 Yes 96 (31.5) 45 (24.6) 51 (41.8)  
Married     
 No 214 (70.2) 138 (75.4) 76 (62.3) 0.0142 
 Yes 91 (29.8) 45 (24.6) 46 (37.7)  
Current homelessness     
 No 227 (74.4) 124 (67.8) 103 (84.4) 0.0011 
 Yes 78 (25.6) 59 (32.2) 19 (15.6)  
Life stressors     
 0 or 1 stressors 126 (41.3) 74 (40.4) 52 (42.6) 0.7041 
 2 or more stressors 179 (58.7) 109 (59.6) 70 (57.4)  
     
Substance Use     
Ever alcohol use     
 No 89 (29.4) 52 (28.7) 37 (30.3) 0.7645 
 Yes 213 (70.6) 129 (71.3) 85 (69.7)  
Current alcohol use     
 No 206 (67.5) 129 (68.9) 80 (65.6) 0.5491 
 Yes 99 (32.5) 57 (31.2) 42 (34.4)  
Ever drug use     
 No 127 (41.6) 65 (35.5) 62 (50.8) 0.0079 
 Yes 178 (58.4) 118 (64.5) 60 (49.2)  
Current drug use     
 No 236 (77.4) 134 (73.2) 102 (83.6) 0.0337 
 Yes 69 (22.6) 49 (26.8) 20 (16.4)  
a N of each variable varies due to missing data; b comparing Study A and Study B  
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 Table 2: Completion rates  by study group  
 






Overall 45.9% (139/302) 38.7% (70/181) 56.6% (69/122) 
    
Age group    
40+ 52.2% (71/136) 41.6% (32/77) 66.1% (39/59) 
<40 40.7% (68/167) 36.5% (38/104) 47.6% (30/63) 
p-value 0.0459 0.4929 0.0396 
    
Gender     
 Female 44.0% (48/109) 40.0% (30/75) 52.9% (18/34) 
 Male 46.9% (91/194) 37.7% (40/106) 58.0% (51/88) 
p-value 0.6303 0.7580 0.6165 
    
Race/Ethnicity    
 Black or African-American 39.7% (62/156) 35.3% (42/119) 54.1% (20/37) 
 Latino 42.9% (27/63) 41.0% (16/39) 45.8% (11/24) 
 African 61.0% (36/59) 61.5% (8/13) 60.9% (28/46) 
 Other 56.0% (14/25) 40.0% (4/10) 66.7% (10/15) 
p-value 0.0283 0.3160 0.5340 
    
Place of birth    
 US-born 40.3% (58/144) 35.0% (36/103) 53.7% (22/41) 
 Foreign-born 50.9% (81/159) 43.6% (34/78) 58.0% (47/81) 
p-value 0.0628 0.2373 0.6458 
    
Education – completed high school    
 No 47.7% (62/130) 44.6% (37/83) 53.2% (25/47) 
 Yes 45.4% (74/163) 34.1% (30/88) 58.7% (44/75) 
p-value 0.6957 0.1603 0.5527 
    
Employment    
 No 42.0% (87/207) 37.5% (51/136) 50.7% (36/71) 
 Yes 54.2% (52/96) 42.2% (19/45) 64.7% (33/51) 
p-value 0.0485 0.5729 0.1238 
    
Married    
 No 39.4% (84/213) 35.0% (48/137) 47.4% (36/76) 
 Yes 61.1% (55/90) 50.0% (22/44) 71.7% (33/46) 
p-value 0.0005 0.0762 0.0085 
    
Current homelessness    
 No 50.2% (113/225) 43.4% (53/122) 58.3% (60/103) 
 Yes 33.3% (26/78) 28.8% (17/59) 47.4% (9/19) 
p-value 0.0099 0.0582 0.3792 
    
Life stressors    
 0 or 1 stressors 52.0% (65/125) 43.8% (32/73) 63.5% (33/52) 
 2 or more stressors 41.6% (74/178) 35.2% (38/108) 51.4% (36/70) 
 0.0730 0.2411 0.1848 
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Ever alcohol use    
 No 56.8% (50/88) 49.0% (25/51) 67.6% (25/37) 
 Yes 41.3% (88/213) 34.4% (44/128) 51.8% (44/85) 
p-value 0.0141 0.0692 0.1055 
    
Current alcohol use    
 No 48.5% (99/204) 40.3% (50/124) 61.3% (49/80) 
 Yes 40.4% (40/99) 35.1% (20/57) 47.6% (20/42) 
p-value 0.1831 0.5018 0.1490 
    
Ever drug use    
 No 51.6% (65/126) 46.9% (30/64) 56.5% (35/62) 
 Yes 41.8% (74/177) 34.2% (40/117) 56.7% (34/60) 
p-value 0.0922 0.0938 0.9810 
    
Current drug use    
 No 47.9% (112/234) 40.9% (54/132) 56.9% (58/102) 
 Yes 39.1% (27/69) 32.7% (16/49) 55.0% (11/20) 
p-value 0.20086888273y 0.3109 0.8779 
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 Table 3: Binomial regression analysis of predictors of completion of care, controlling for study of origin 
 










Demographics      
Age 40+ years 
 
-0.2437 0.1206 0.7837 0.6188-0.9927 0.0433 
Male 
 
0.0200 0.1293 1.0202 0.7918-1.3146 0.8770 
Race/Ethnicity      
   African vs. African-American 
 
0.2609 0.1653 1.2981 0.9388-1.7950 0.1145 
   Latino vs. African-American 
 
0.0189 0.1767 1.0191 0.7208-1.4408 0.9148 
Foreign-born 
 
0.1459 0.1302 1.1571 0.8965-1.4935 0.2624 
Social Characteristics      
Completed high school 
 
-0.0560 0.1221 0.9455 0.7443-1.2011 0.6463 
Employed 
 
0.1971 0.1228 1.2179 0.9573-1.5494 0.1086 
Married 
 
0.3917 0.1180 1.4795 1.1740-1.8646 0.0009 
Currently homeless 
 
-0.3283 0.1755 0.7201 0.5106-1.0157 0.0613 
Life stressors – 2 or more 
 
-0.2142 0.1199 0.8072 0.6381-1.0210 0.0740 
Substance Use      
Ever alcohol use 
 
-0.3015 0.1193 0.7397 0.5854-0.9346 0.0115 
Current alcohol use 
 
-0.2046 0.1381 0.8150 0.6218-1.0683 0.1385 
Ever drug use 
 
-0.1302 0.1244 0.8779 0.6879-1.1204 0.2953 
Current drug use 
 
-0.1330 0.1639 0.8755 0.6350-1.2071 0.4171 
RR = Risk Ratio   
CI = Confidence Interval 
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 Table 4: Multivariate binomial regression analysis of predictors of completion of care 
 












-0.3445 0.1765 0.7086 0.5014-1.0014 0.0509 
Married 
 
-0.6538 0.3958 0.5200 0.2394-1.1295 0.0985 
Interaction married*foreign-born 
 
1.2817 0.4276 3.6029 1.5583-8.3298 0.0027 
Currently homeless 
 
-0.5060 0.2263 0.6029 0.3869-0.9394 0.0253 




0.1511 0.7586 0.5642-1.0200 0.0674 
Interaction  currently 
homeless*current alcohol use 
 
0.8806 0.3420 2.4122 1.2339-4.7158 0.0100 
Study of origin* 
 
-0.3276 0.1186 0.7206 0.5711-0.9093 0.0058 
RR = Risk Ratio   
CI = Confidence Interval 
* Study A = 1, Study B = 0 
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Table 5: Binomial regression analysis of knowledge & attitude predictors of completion of care, 
controlling for study of origin 
 










Knowledge items      
K1. Can get TB from crowded conditions 
 
0.1457 0.2356 1.1569 0.7291-1.8357 0.5362 
K2. Can get TB through kissing 
 
0.1310 0.1337 0.1400 0.8772-1.4814 0.3271 
K3. Can get TB through sharing dishes 
 
-0.1093 0.1418 0.8965 0.6789-1.1837 0.4408 
K4. Most TB can be cured with medications 
 
0.4321 0.3668 1.5405 0.7506-3.1616 0.2389 
K5. HIV-infected more likely to get TB 
 
-0.1289 0.1355 0.8791 0.6740-1.1465 0.3416 
K6. People with TST+ may need TB medications 
 
0.0362 0.2981 1.0368 0.5780-1.8598 0.9034 
Knowledge score 
 
0.0130 0.0627 1.0130 0.8960-1.1454 0.8363 
Attitudinal variables      
A1. TB is disease you have to take seriously 
 
-0.0613 0.1181 0.9405 0.7462-1.1854 0.6036 
A2. Taking TB medications is important 
 
-0.1076 0.0799 0.8980 0.7678-1.0503 0.1783 
A3. You know better than the doctor when best 
to stop medications 
 
-0.0322 0.0744 0.9683 0.8368-1.1204 0.6652 
A4. Going to appointments more trouble than 
worth 
 
0.0172 0.0758 1.0174 0.8769-1.1804 0.8201 
A5. If do the right thing, can avoid getting TB 
 
0.0047 0.0542 1.0047 0.9034-1.1173 0.9313 
A6.  No matter what you do, can get TB      
   strongly disagree -0.4083 0.1615 0.6648 0.4844-0.9124 0.0115 
   disagree -0.0001 0.1800 0.9999 0.7026-1.4232 1.0000 
   agree -0.0677 0.1551 0.9345 0.6896-1.2666 0.6626 
   strongly agree 
 
reference     
A7. Embarrassed to tell you have TB      
   strongly disagree -0.3380 0.1409 0.7132 0.5411-0.9401 0.0164 
   strongly agree -0.2811 0.1533 0.7550 0.5590-1.0195 0.0666 
   disagree/agree 
 
reference     
A8. Believe have TB germ      
   strongly disagree -0.2536 0.1638 0.7760 0.5629-1.0697 0.1215 
   strongly agree -0.4264 0.1323 0.6529 0.5038-0.8461 0.0013 
   disagree/agree 
 
reference     
A9. Care about what family/friends think      
   strongly disagree -0.3031 0.1654 0.7385 0.5341-1.0212 0.0668 
   strongly agree -0.3488 0.1431 0.7055 0.5330-0.9340 0.0148 
   disagree/agree 
 
reference     
A10. As hard as you try, you are going to miss 
some of your medicines 
     
   strongly disagree  -0.5324 0.3343 0.5872 0.3049-1.1308 0.1113 
   disagree  0.2079 0.1566 1.2311 0.9057-1.6735 0.1844 
   agree  -0.0149 0.1455 0.9852 0.7408-1.3102 0.9184 
   strongly agree reference     
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A11. TB medications are a hassle      
   strongly disagree -0.1929 0.1350 0.8246 0.6329-1.0742 0.1529 
   strongly agree -0.6941 0.4493 0.4995 0.2071-1.2050 0.1224 
   disagree/agree 
 
reference     
A12. Takes something bad to not take meds      
   strongly disagree  -0.0579 0.1560 0.9437 0.6951-1.2802 0.7104 
   disagree  0.2070 0.1952 1.2300 0.8389-1.8033 0.2891 
   agree  0.1735 0.1745 1.1895 0.8448-1.6746 0.3202 
   strongly agree 
 
reference     
RR = Risk Ratio   





 Chapter 5: 








RATIONALE: Few randomized controlled trials have examined the impact of interventions for 
improving treatment completions rates of latent TB infection (LTBI).  
OBJECTIVE: To assess the effectiveness of a peer-based experimental intervention on 
adherence to and completion of LTBI treatment in patients eligible for LTBI treatment in an 
urban clinic setting.  
METHODS: Patients diagnosed with LTBI in an urban chest clinic were recruited for two NIH-
funded sequentially-conducted randomized controlled trials for experimental intervention of self-
administered treatment of LTBI with peer support versus control of standard of care self-
administered treatment alone.  The Pathways study enrolled participants between 1996-1999 and 
TAPAS enrolled participants between 2002-2005.  Adherence support was provided by trained 
peer workers who were community members and had successfully completed either TB or LTBI 
treatment.  The primary outcomes were treatment adherence and completion.  Demographics, 
social support, mental health, TB knowledge and attitudes, and substance use were assessed at 
baseline and follow up appointments.  Adherence was also assessed by self report, electronic 
monitoring devices and through clinic visits. 
RESULTS: Of 360 participants enrolled in Pathways, 58% were male, 71% Black, 23% Latino.  
Mean age was 40 years, 48% were foreign-born, 54% completed high school, 26% were married.  
Participants in the control group reported significantly more homelessness and drug use at 
baseline.  In Pathways, 60% of participants in the intervention group completed treatment of 
LTBI compared to 38% of controls (p<0.0001).  In multivariate analysis, completion of high 
school and current homelessness, were found to be predictors for non completion of LTBI 
treatment after controlling for intervention group.  Additionally, agreement with two attitudinal 
items (“doctors don’t really care about curing your TB,” and “when feel real bad, you would stay 
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 home instead of seeing the doctor,”) was identified as predicting non completion of LTBI 
treatment.  Adherence analysis was not possible as many of the monthly adherence interviews 
were lost and could not be located.  Of 250 participants enrolled in TAPAS, 70% were male, 
71% Black, and 20% Latino.  Mean age was 39 years, 67% were foreign-born, 61% completed 
high school, and 39% were married.  No significant differences were noted in baseline 
characteristics between groups.  In TAPAS, 61% of participants in the intervention group 
completed treatment of LTBI compared to 57% of controls (p=0.4818).  Corresponding LTBI 
treatment completion rate for clinic patients who did not participate in the study was 44%.  
Foreign birth, marriage, and history of mental illness were found to be predictors for non 
completion of LTBI treatment after controlling for intervention group; however, increased 
completion rates were found among married persons of foreign-birth.  Older age (40+) was a 
predictor of improved treatment completion.  Results of the medication adherence analysis in 
TAPAS demonstrated a substantial difference in adherence rates was observed between study 
groups (10%) and that non-completers’ adherence decreased early during treatment while 
completers had fairly steady levels of adherence throughout the treatment.     
CONCLUSIONS: The peer support intervention was found to be associated with significant 
increase in LTBI treatment completion rates in the Pathways population but not in the TAPAS 
population, whereas completion rates increased in the control group as well as in the intervention 
group in the latter study.  The power for detecting an intervention effect in TAPAS was reduced 
by the higher than expected completion rates in both groups; however, the effect of the TAPAS 
intervention is statistically significant in the adherence model.  Adherence analysis in TAPAS 
suggests that it is important to intervene early in the treatment as the first two months of 
treatment present a danger period where patients tend to default treatment.  
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 INTRODUCTION 
An estimated 9 to 14 million persons in the United States have latent tuberculosis infection 
(LTBI) and are therefore at risk for progression to active tuberculosis (TB) disease.1  Diagnosis 
and treatment of LTBI has been identified by the Centers for Disease Control and Prevention as 
one of the major strategies for elimination of tuberculosis (TB) in the U.S.2  Similarly, the 
Institute of Medicine has called for programs of targeted tuberculin testing coupled with 
treatment of LTBI (TLTBI) for individuals with elevated risk of developing TB disease.3  
Completion of treatment for latent tuberculosis infection (TLTBI) is key to reducing the 
incidence of active TB in the US.  It has been estimated that 200,000-300,000 individuals are 
treated for LTBI in the U.S. annually.4  However, TLTBI completion rates in the U.S. generally 
has been  largely below established targets and have been reported to range from 20 to 65% for a 
6-month course of self-administered treatment; a few smaller studies were able to achieve higher 
completion rates.5  A large multi-site study reported recently that treatment completion rates of 
the standard 9-month isoniazid regimen range from 30-60%,4 
Over the past decade, several studies in the U.S. have evaluated the effect of different 
interventions aimed at improving adherence to TLTBI.  These  interventions included use of  
supervised therapy and the use of supplementary tools to promote adherence such as the 
provision of monetary incentives, counseling services, peer education programs, and health 
professional or cultural case management.5  However, there are few LTBI adherence 
interventions that have been rigorously tested in randomized controlled trials.5  In addition, most 
LTBI adherence interventions in the US have focused on specific populations, such as jail or 
prison inmates, injection drug users, homeless persons, health care workers, and immigrants or 
refugees originating from TB-endemic countries.  
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 Peer collaboration has been recognized as a powerful tool to build social support in relation to 
adherence.6-9  Peer workers, also called peer educators, peer advisors, lay health advisors or 
community health workers, have been matched to patients on the basis of their shared ethnicity, 
gender, illness experience, sexual orientation, risk behaviors, and/or socio-economic 
characteristics.10-12  They act as system navigators to help patients secure social and community 
services needed for successful treatment completion, liaise with patients and health workers to 
enhance patient-provider communication, educate and coach patients on adherence behaviors, 
and provide social and emotional support.  Peer interventions cultivate “helping relationships” 
that bond patient and peer in a uniquely personal alliance for health promoting behaviors.  
Because they facilitate tailoring treatment to individual patient needs, peer workers may be 
particularly valuable in interventions that target the complex interaction of factors known to 
influence adherence. 
To date, peer-based interventions have demonstrated mixed results in facilitating optimal 
medication-taking behavior for LTBI, although few randomized controlled trials have assessed 
the effectiveness of peers to improve adherence to and completion of LTBI treatment.5  Chaisson 
et al. found that electronically monitored adherence was significantly higher subsequent to the 
implementation of a peer-based adherence intervention with injection drug-using LTBI patients 
in Baltimore.13  Tulsky et al. evaluated the effect of peer health advisors for homeless LTBI 
patients; 118 participants were randomized to receive DOT with an incentive, DOT with peer 
support, or self-administered therapy.  LTBI treatment completion was significantly higher 
among those given an incentive, and there was no difference between peer-assigned and SAT 
groups (44% vs. 19 and 26% respectively).  Failure was attributed to poor training of peer 
advisors on TB prevention education.14  Further research is needed to assess the quality, range 
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 and sustainability of peer interventions, and impact needs to be assessed in relation to the clinical 
and social context of the patient population to which the intervention is directed.   
The effectiveness of peer workers or peer advisors in the management of LTBI merits further 
exploration.  This analysis uses data from two sequential NIH-funded randomized controlled 
trials, Pathways to Completion Study and the Tuberculosis Adherence Partnership Alliance 
Study (TAPAS), to assess the impact of a peer-based experimental intervention on adherence to 
and completion of LTBI treatment in a general clinic population in an urban setting in the U.S. 
 
METHODS 
Design, setting and sample 
From 1996 through 1999, patients who were diagnosed with LTBI were recruited from the 
Harlem Hospital Chest Clinic in New York City into the Pathways to Completion study, and 
from 2002 through 2005 into the TAPAS study.  With TB rates greatly exceeding the national 
average and the concomitant HIV epidemic, the Harlem community is vulnerable to TB.  Many 
of the patients in the clinic are referred by homeless shelters, substance abuse programs, and 
community based organizations where TB skin testing is often required for residency or for 
services like English language classes.   
Patients in the clinic were offered treatment for LTBI (TLTBI) by their providers in the TB 
Clinic based on the prevailing CDC/ATS guidelines to determine candidacy for TLTBI.2  The 
specific criteria used to determine study eligibility were as follows: 
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 Inclusion Criteria: 
o Recommended for initiation of a CDC recommended drug regimen for TLTBI 
o Age of 18 years or older 
Exclusion Criteria:  
o Receiving Directly Observed Therapy for LTBI 
o Evidence of active TB disease 
Patients who fulfilled these criteria were referred for study participation.  Potential study 
candidates were provided with further information regarding the study and invited to participate. 
All participants signed a consent form approved by the Columbia University Institutional Review 
Board at Harlem Hospital.  Following a baseline interview with a research assistant, participants 
were randomly assigned to either the intervention or control group. 
Experimental Intervention    
Both studies assessed a peer-based intervention for LTBI treatment in the Harlem population.  
The peer intervention was compared to traditional self-administered treatment of LTBI.  
Building on experiences and insights from the Pathways study, the TAPAS intervention utilized 
the Health Belief Model,15,16 Social Learning Theory,17 and the Precaution Adoption Process 
(PAPM) Model,18 enriched by social support concepts.  This resulted in a more structured, 
theory-based intervention in TAPAS than in Pathways.  The experimental intervention was 
primarily provided by peers who delivered components tailored to the PAPM model with the 
ultimate goal of achieving treatment completion.  In addition, targeted health education was 
provided for selected patients in the TAPAS experimental arm.  All study participants had access 
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 to the standard clinical services available at the clinic, including a social worker and clinic health 
educators.   
Peer worker qualifications included: successfully completing TB or LTBI treatment; being 
members of the communities that patients came from; having good communication skills; 
demonstrating a caring attitude; and being committed to TB control.  The peer workers 
underwent extensive training that included both didactic learning and interactive techniques such 
as case study and role-playing to develop skills.  The peer workers’ role was designed to include 
the following elements: system navigation, referrals, advocacy, and social support.  Peer worker 
responsibilities included: communicating weekly with participants; providing information on the 
importance of treatment; encouraging medication and visit adherence; offering support and 
empathy; providing referrals; and advocating for their participants.   
Study Measurements  
Questionnaires that evaluate key demographic, social, and behavioral characteristics were 
administered at baseline.  Data were gathered from interviews and abstracted from participant 
clinic charts.  Participants were recruited over two three-year periods and were followed at 
monthly intervals until they completed treatment, stopped treatment without completing it 
(possibly on medical advice), or were lost to follow-up.  Participants were asked to return to the 
clinic each month in order to obtain medication refills and to be monitored for side effects from 
the medication as per standard of care.  Participants were given coupons for transportation and 
lunch after each interview.  The interviewers were research assistants who had extensive 
interviewing experience and who received special training for this study.  The questionnaires 
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 were translated into French and Spanish and interviews were conducted in English, French, and 
Spanish.  Completed interviews were reviewed by the study coordinators for completeness.   
In both studies, information on participants’ socio-demographic characteristics, history of 
substance use, social support, life stressors, and TB knowledge and attitudes was obtained from 
interviews at baseline using structured questionnaires.   
Social support was assessed with a modified version of the University of California, Los Angeles 
Social Support Inventory,19 which measures three dimensions of social support over the previous 
month.   TB knowledge and attitudes instrument was developed by the study investigators based 
on their experience in this field.  The Knowledge section included True/False knowledge items 
related to TB transmission, symptoms, diagnosis and treatment; it included 24 items in Pathways 
and 16 items in TAPAS.  The Attitudes section was comprised of attitudinal items measured on a 
four-point Likert scale and based on constructs suggested by key theoretical models (such as the 
Transtheoretical Model of Behavior Change, Social Learning, and the theory of Reasoned 
Action); it included 24 items in Pathways and 14 items in TAPAS.  Constructs for attitudinal 
items included intentions, perceived risk, perceptions of group norms, self-efficacy, cues to 
action and costs and benefits.   
Stressful life events were measured using a structured instrument which included assessment for 
issues such as financial distress, death, legal matters, violence, and partner separation in the past 
6 months.20  Information collected from the substance use instrument was used to classify study 
participants as substance or non-substance users;21 current use was defined as past month use.  A 
brief standardized version of the Marlowe-Crowne Social Desirability Scale questionnaire was 
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 conducted as an adjunct measure to assess the impact of social desirability on self-report 
measures.22 
Additional data collection measures for the TAPAS study included, quality of life using the SF-
12, which assesses limitations of activities due to physical and mental health.23,24  Depression 
was assessed using the Center for Epidemiologic Studies Depression (CES-D) Scale, a 20-item 
self-report instrument designed to assess depressive symptoms in the general population over the 
past week; scores greater than or equal to 16 are interpreted as a positive screen for depression.25  
The perceived benefits/perceived barriers questionnaire was based on decisional balance scales 
developed for contraceptive use,26 with the content of the benefits/barriers incorporating input 
from providers and patients who were on treatment for LTBI at the time.   
LTBI treatment completion was determined by the participants’ medical providers, who were 
blinded to study status and made clinical determination of TLTBI completion/non-completion 
according to CDC guidelines; these data were subsequently abstracted from medical charts by 
research staff.  Information on initiation and completion of therapy, treatment interruptions, and 
adherence with clinic appointments was abstracted from the medical chart.   
Treatment adherence was assessed in both studies on a monthly basis.  In Pathways, a brief 
monthly assessment of adherence was conducted but many of the interviews were lost and could 
not be located; this did not allow for meaningful imputation of adherence data.   
In TAPAS, a monthly assessment of adherence was conducted utilizing a combination of tools 
including self-report, clinic attendance, and electronic monitoring devices.  The first two 
measures were utilized because they are informative, easy to use and replicate programmatically, 
and are not too costly or cumbersome for this patient population.  Electronic monitoring devices 
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 are costly and have been reported to be cumbersome;27-29 however, it was thought that they 
would be useful for measuring adherence in the context of a clinical trial.  The self-report 
adherence questionnaire was administered by interview; it evaluated adherence through an in-
depth assessment of pill-taking behavior during the prior three days modeled on a validated 
ACTG self repot adherence questionnaire.  In addition, detailed use of the MEMS caps was 
ascertained by interview; participants were asked whether they removed multiple doses of 
medications or opened and closed the cap without removing the medications.  Acceptability of 
the MEMS cap in this population was assessed by interview at the end of the study.  Prescription 
bottles equipped with the Medication Event Monitoring System (MEMS®) cap were distributed 
to all participants and collected at each monthly visit.  The MEMS utilizes an electronic device 
built into the cap of the prescription bottle that records the date and time that the cap is removed.  
Clinic visit adherence was tracked for all participants throughout the study by the research 
assistants, who abstracted information from clinic charts and schedules.  The monthly follow up 
questionnaire also elicited information about possible reasons for missing medications.  
Participants were asked to react to 25 different possible reasons on a 4-point scale: Never, 
Rarely, Sometimes, and Often.  
Sample Size 
The sample size for the Pathways study was based on the assumption that 55% of the 
intervention arm and 40% of the usual care arm would complete LTBI treatment.  Under these 
assumptions, 151 participants per arm would be sufficient to provide 80% power for testing the 
primary hypothesis.  The sample size was increased to 180 participants per arm to allow for 
attrition and to increase the power to assess secondary objectives.  The sample size for the 
TAPAS study was based on the assumption that 60% of the intervention arm and 40% of the 
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 usual care arm would complete LTBI treatment, based on results seen in the Pathways study.  
Under these assumptions, 97 participants per arm would be sufficient to provide 80% power for 
testing the primary hypothesis.  The sample size was increased to 125 participants per arm to 
allow for attrition and to increase the power to assess secondary objectives. 
Randomization 
Both studies used a 1:1 randomization design. The random sequence of group assignment was 
allocated in a permuted 10-block design, generated by a study investigator.  Cards indicating 
study group assignment were sealed in numbered, opaque envelopes and retained by the study 
coordinator.  After completing the baseline assessment with study research assistants, 
participants were informed by the study coordinator of their random assignment to the peer 
support or usual care group. 
Blinding 
Due to the nature of the peer intervention, it was not possible to blind participants and 
intervention staff to their group assignment.  Every attempt was made to ensure blinding of the 
research assistants, who conducted all follow up interviews.  
Statistical Methods 
Imputation of Missing Adherence Data 
In TAPAS, self-reported adherence over the treatment period was one of the two primary 
outcomes for this study.  For subjects who were missing self-reported adherence data at any time 
point, imputation procedures were implemented.  The first step involved filling in missing data 
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 based on decision rules developed for this project (see Appendix 2 Table 6 for more details), 
which  utilized information from the chart abstraction and electronic adherence monitors (MEMS 
caps).  For example, these rules involved assigning zero adherence for months 2-9 to patients 
whose charts noted that they were never seen in the clinic after the first appointment.  For those 
data points where it was not possible to impute values based on all available information, hot-
deck imputation was used.30  Imputation was considered essential to (1) construct as complete a 
longitudinal database as possible and (2) correct bias due to data missing not at random.31  The 
hot deck method was chosen because it was the most appropriate given the patterns of missing 
data.  To implement hot-deck imputation, respondents with a missing adherence score at any 
time point constituted a pool of potential donors, while those missing this information were the 
recipients. The first critical “boundary” for imputation was whether or not persons completed 
treatment. Only donors who completed were used to impute missing data for completers; only 
donors who did not complete treatment were used to impute missing data for non-completers. 
Recipients were matched to donors based on the months for which data was available and 
matched to within +/- 2 months, and the actual reported adherence during these months had to 
match to within a cutoff of +/- 25%.  Each recipient was then assigned a value from a matching 
donor; in cases of multiple matching donors, one donor was selected at random (See Appendix 2 
Table 7 for more details). 
Data Analysis 
All data analyses were performed in accordance with the intent-to-treat principle.  The effect of 
the intervention on treatment completion consisted of comparing proportions of subjects who 
were classified as either success or failure based on completion of therapy.  Analysis was 
conducted using Pearson’s χ2 test, or Fisher exact test where appropriate, for categorical 
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 variables and student’s t-test for continuous variables.  The potential confounding role of 
homelessness, substance use, social support, TB knowledge and attitudes, and other independent 
risk factors for non-adherence on the association between completion of therapy and intervention 
group was examined using stratified analyses and Mantel-Haenszel summary measures.  Due to 
the large number of prognostic factors, data reduction techniques were used (see below).  
Variables significant at 0.10 or less were candidates for the final models.  Multivariate binomial 
regression was used to 1) analyze the impact of the experimental intervention on completion of 
therapy after adjusting for variables identified as significant in the bivariate analyses, 2) 
potentially confounding variables reported in previous studies, and 3) interaction terms.  Models 
were constructed based on a manual, stepwise assessment of potential predictors and 
hypothesized interactions.  Model diagnostics were computed for final models and assessed 
using the Hosmer and Lemeshow Goodness-of-Fit Test, along with Akaike’s Information 
Criteria (AIC) and Schwartz’s Information Criterion (SIC).32-34 
For the effect of the intervention on adherence, treatment adherence over time was modeled 
using mixed effects repeated measures models to further evaluate the impact of study arm on 
adherence.  Repeated measures analysis uses all longitudinal data accounting for correlations in 
the data resulting from multivariate observations, clustering, or repeated measurements, and 
potentially has more power for comparing the intervention and standard of care arms.  A Toeplitz 
covariance structure was used in the mixed effect models.  This covariance structure assumes 
that the covariance between any two consecutive time points is the same but may be different 
from two time points that are separated by observations.  For example, the covariance between 
time points 1 and 2 is same as time 2 and 3 but is different than the covariance between time 1 
and 3 or 2 and 4, which are equal to each other.   
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 The current standard for graphically displaying and exploring longitudinal data is the use of 
spaghetti plots, which involves plotting each subject’s values for the repeated outcome measure 
(vertical axis) versus time (horizontal axis) and connecting the dots chronologically.  However, 
there are a number of limitations to spaghetti plots such as trajectories commonly overlapping 
and with large datasets, the resulting plot is often a confusing jumble of intersecting lines with no 
discernible patterns.  To be able to discern adherence patterns in this dataset, spaghetti plots were 
utilized with an addition of a small random variation for each datapoint.  Because of the 
problems with spaghetti plots, heatmaps were used as a complementary graphical data 
exploration technique.35  Heatmaps use color or shading to depict the magnitude of the outcome 
measurement and fix the vertical dimension per subject and thus each subject forms a “layer” in 
the plot.  The plot takes advantage of color to provide a third dimension and display information 
clearly, rather than relying upon the vertical dimension to display overlapping magnitudes of 
change.  There are several advantages of the heatmaps over the spaghetti plots in this type of 
longitudinal data. Group, cohort, and individual level information are preserved regardless of the 
number of subjects or time points. In addition, dynamic sorting of the data can be used to 
ascertain group level behavior over time.35 
To assess whether MEMS data provided reliable data that can be used to impute adherence data 
where it was missing, a comparison of MEMS and self report was conducted.  For each available 
interview, the MEMS data was reviewed for the corresponding three days prior to the interview 
date.  Modified MEMS-use interviews were reviewed to check for reports of removing multiple 
doses of medications in the three days prior to interview day.  A kappa statistic was calculated to 
measure the agreement between the two sources of data.  The criteria employed to determine fair 
to good agreement was kappa of 0.40-0.75.36  
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 Data Reduction 
Factor analysis was used to develop scale scores for attitudes as well as for reasons given by 
participants for missing medications.  Principal components analysis was utilized with a varimax 
rotation method in order to produce factors that were orthogonal or uncorrelated.  Two criteria 
were employed to determine the number of factors to be retained: (a) Kaiser-Guttman’s criterion 
(i.e., factors with an eigen value of greater than 1), and (b) examination of the scree plot.  A 
factor loading of 0.50 was selected as the minimum level for item inclusion in a factor.  Scales 
were produced by taking the mean score for all items in a specific factor.   
A summary knowledge variable was constructed by calculating the proportion of correct answers 
to True/False knowledge items.  A social support scale was created by taking the mean of the six 
social support items.  Perceived benefits and barriers scales were created by taking the mean of 
the benefit items and barrier items respectively.  Internal consistency reliability of scales was 
tested with Cronbach’s alpha; the criteria employed to determine reliable scales was Cronbach’s 
alpha greater than or equal 0.6.37   
Statistical analyses were performed using SAS (version 9.2, 2000; SAS Institute Inc, Cary, NC) 






 RESULTS - PATHWAYS 
Enrollment  
Figure 1a describes participant enrollment from July 1996 through June 1999.  A total of 866 
patients evaluated for LTBI were approached and of these, 536 were determined to be eligible 
for the study and were invited to participate.  Twenty four of eligible patients refused to 
participate in the study; 153 were missed as study staff was not present to interact with potential 
candidates prior to initiation of treatment for LTBI; and 379 provided informed consent, 
completed baseline interviews, and were randomized to the peer support intervention or to the 
usual care arm, according to the study group allotment procedures described above.  Ten 
participants (four intervention and six usual care participants) were determined to be ineligible 
for LTBI and were discharged by the clinic.  In addition, nine participants (seven intervention 
and two usual care participants) were determined to be ineligible for the study according to 
inclusion criteria following randomization and are not included in study results.  At the end of 
assigned treatment, three medical records could not be located: one intervention participant and 
two usual care participants and were therefore lost to follow up. Since the primary outcome was 
based on review of the medical records and to be conservative, it is assumed that these 
participants did not complete treatment.   
Study Population  
The Pathways Study recruited 379 participants, 188 were randomized to the intervention group 
and 191 to the control group.  After excluding ineligible participants, the intervention group 
included 177 participants and the control group 183 participants (Table 1).  The sample was 
predominantly male (58%), and study participants were 40 years old on average.  The racial 
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 distribution of the sample was Black (71%), Latino (22%) and White/other (7%).  
Approximately half completed high school or had a GED equivalent (54%).  A quarter reported 
they were married/common law (26%) and almost half (48%) were foreign-born.  Over a third of 
participants (38%) reported a history of homelessness and 26% reported current homelessness.  
Unemployment rates were high in this population with 73% of participants unemployed at 
baseline.  A small proportion of participants (5%) reported HIV-infection at baseline; however, 
close to half (43%) did not know their HIV status.  Substance use was reported by a third of the 
sample (33%) currently drinking alcohol and 22% currently using illicit drugs.  There were no 
statistically significant differences between study arms with the exception of participants in the 
control group reporting more homelessness and lifetime drug use.  The Marlowe-Crowne scale 
was used as an adjunct measure to assess the impact of social desirability on self-report 
measures; the reliability of the instrument was examined and it was found to be reliable.  
However, the mean Marlowe-Crowne scales did not differ significantly between study arms, 
indicating there was no apparent difference in participants’ attempts to provide socially desirable 
responses.   
LTBI Treatment Completion Rates 
Overall, 48.9% of participants completed therapy. Table 2 presents a comparison of completion 
in the two study arms that suggests that the intervention was effective with 59.9% of participants 
in the intervention group completing treatment versus 38.3% in the control group (RR=1.561, 
95% CI 1.255-1.942).  Both groups had similar proportions of adverse events or medical issues 
(data not shown).  
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 Table 3 summarizes binomial regression analysis of individual predictors of treatment 
completion, while controlling for study group.  That is, each model contains coefficients for the 
predictor and treatment/control group.  Completion of high school (ARR=0.782, 95% CI 0.638-
0.957), current homelessness (ARR=0.696, 95% CI 0.516-0.938), current smoking (ARR=0.789, 
95% CI 0.641-0.972), and lifetime drug use (ARR=0.805, 95% CI 0.657-0.986) were the only 
strongly significant predictors for non-completion of treatment for LTBI.   
The social support instrument was not found to be reliable (α=0.475) and therefore was not used.  
Individual social support items were examined and one item which stated “there are people you 
feel you can talk to about personal or private matters” was positively associated with completion 
(ARR=1.248, 95% CI 1.035-1.506).   
The overall knowledge score was not significantly associated with completion of treatment.  Of 
24 knowledge items, three correct answers were found to be significant predictors of non-
completion, or showed a trend, in models with treatment group. These items include: “TB skin 
test is a vaccination against TB” (ARR=0.812, 95% CI 0.664-0.993), and “a person with a 
positive skin test may need to take TB medications” (ARR=0.705, 95% CI 0.552-0.901), and 
“HIV infected persons are more likely to get TB” (ARR=0.814, 95% CI 0.653-1.014). 
Factor analysis of the 24 attitudinal items in the questionnaire yielded 10 factors accounting for 
56.4 percent of the total variation.  Some attitudes did not load on any of the factors; therefore, 
the analysis was rerun excluding these variables so that the relative importance of each of the 
remaining items could be assessed.  Seven factors including 17 variables emerged accounting for 
57.6 percent of the total variation (Appendix 1, Table 2 and Figure 1).  Final factor solution is 
shown in Appendix 1, Table 3.  Seven scales were created but no reliable scales were found or 
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 retained (Appendix 1, Table 1).  The distribution of each attitudinal item was inspected carefully 
to examine its distribution.  Depending on the distribution, the category with most responses was 
designated as the reference group or the two middle categories (‘agree’ and ‘disagree’) were 
collapsed and used as the reference group.  When examining the 24 attitudinal items 
individually, 10 were found to be significant, or showed a trend, in models with treatment group.  
Agreeing with the following statements was associated with lower treatment completion: “you 
are not embarrassed to tell people you have TB” (ARR=0.752, 95% CI 0.584-0.967), “your 
family/friends don’t care if you keep appointments or take medications” (ARR=0.888, 95% CI 
0.773-1.020), “doctors don’t really care about curing your TB” (ARR=0.359, 95% CI 0.145-
0.887), “you care about what family/friends think of treatment (ARR=0.747, 95% CI 0.590-
0.946), and “no matter what you do, you can still get TB” (ARR=0.747, 95% CI 0.597-0.934).  
The statement “you believe you have the TB germ”, was associated with lower completion 
regardless of agreement (ARR=0.771, 95% CI 0.619-0.960) or disagreement (ARR=0.753, 95% 
CI 0.568-0.998).  Similarly, “as hard as you try, you are going to miss some of your 
medications”, was associated with lower completion regardless of agreement (ARR=0.557, 95% 
CI 0.357-0.871) or disagreement (ARR=0.814, 95% CI 0.665-0.996); “taking TB medications is 
a hassle”, was associated or showed a trend with lower completion regardless of agreement 
(ARR=0.432, 95% CI 0.180-1.038) or disagreement (ARR=0.792, 95% CI 0.630-0.997); and 
“when you feel really bad, you would stay home instead of seeing doctor” was associated or 
showed a trend with lower completion regardless of agreement (ARR=0.480, 95% CI 0.261-
0.882) or disagreement (ARR=0.836, 95% CI 0.676-1.034).  Another attitudinal item which is 
exhibiting unexpected results is “Taking TB medicines is important” (ARR=0.846, 95% CI 
0.711-1.007), which is associated with lower completion rates.  However, this pattern is only 
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 seen in the control group and moreover, only a small number in the control group agreed with 
this item.  
All predictors significant at 0.10 or less were candidates for the multivariate model. While not 
significant on their own, foreign birth (ARR=1.049, 95% CI 0.855-1.286) and current drug use 
(ARR=0.790, 95% CI 0.591-1.057) were further considered in multivariate models because there 
was an imbalance between the study groups.  According to the multivariate model in Table 4, 
participants in the intervention group were 1.5 times more likely to complete treatment compared 
with those in the control group (ARR=1.504, 95% CI 1.211-1.869).  Completion of high school 
(ARR=0.800, 95% CI 0.656-0.975) and current homelessness (ARR=0.787, 95% CI 0.580-
1.068) were identified as predictors for non-completion of LTBI treatment.  Two attitudinal 
items contributed significantly to this model.  The more likely participants were to agree with the 
statement “doctors don’t really care about curing your TB,” the less likely they were to complete 
treatment (ARR=0.441, 95% CI 0.183-1.065).  Similarly, participants who strongly agreed with 
the statement “when you feel real bad, you would stay home instead of seeing the doctor,” were 
significantly less likely to complete treatment (ARR=0.491, 95% CI 0.257-0.936).  Diagnostic 
statistics were used to assess the validity of the final model.  These diagnostic tests confirmed 






 RESULTS - TAPAS 
Enrollment  
Figure 1b describes participant enrollment from May 2002 through April 2005.  A total of 603 
patients evaluated for LTBI were approached and of these, 444 were determined to be eligible 
for the study and were invited to participate.  Of eligible patients, 163 refused to participate in 
the study (44% were too busy, 26% had no interest, 21% had other reasons, and 8% gave no 
reason); 29 were missed because study staff were not present when decision to initiate treatment 
for LTBI was made by clinicians; and 252 provided informed consent, completed baseline 
interviews, and were randomized to the peer support intervention or to the usual care arm, 
according to the study group allotment procedures described above.  Two participants in the 
control arm were determined to be ineligible to the study according to inclusion criteria 
following randomization and are not included in study results.  At the end of assigned treatment, 
three intervention participant medical records and two standard of care participant records could 
not be located and were therefore lost to follow up in terms of the completion analysis.  Since the 
primary outcome was based on review of the medical records it was conservatively assumed that 
these participants did not complete treatment.  Many participants had partial adherence follow up 
data but we were able to obtain the primary endpoint (completion) from their medical charts and 
analyze their data. 
Study Population 
The TAPAS Study recruited 252 participants, 128 were randomized to the experimental 
intervention group and 124 to the standard of care control group. After excluding ineligible 
participants, the intervention group included 128 participants and the control group 122 
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 participants (Table 5).  The sample was predominantly male (70%), and study participants were 
40 years old on average.  The racial distribution of the sample was African-American (35%), 
Latino (20%), African (36%), and White/other (9%).  More than half of participants indicated 
that they had completed high school or had a GED equivalent (61%).  Two thirds (67%) of 
participants were foreign-born and 39% reported they were married or in common law unions.  A 
history of homelessness was reported by 33% of participants and current homelessness by 16%.  
Unemployment rates were high in this population with 59% of participants unemployed at 
baseline.  History of mental illness as defined by past psychiatric hospitalizations or currently on 
psychiatric medications was reported by 8% of participants. Substance use was reported by 32% 
of the sample currently drinking alcohol and 16% currently using drugs.  Approximately a third 
of the population was depressed by the CES-D measure.  There were no statistically significant 
differences between study arms.  The Marlowe-Crowne was used as an adjunct measure to assess 
the impact of social desirability on self-report measures; the reliability of the instrument was 
examined and it was found to be reliable.  However, the mean Marlowe-Crowne scales did not 
differ significantly between study arms, indicating there was no apparent difference in 
participants’ attempts to provide socially desirable responses.     
LTBI Treatment Completion Rates 
Overall, 58.8% of participants completed therapy.  Table 6 presents a comparison of completion 
in the two study arms; 60.9% of participants in the intervention group completing treatment 
versus 56.6% in the control group (RR=1.096, 95% CI 0.850-1.414).  During the study period, 
1,035 non-study patients in the clinic initiated and 44.0% completed LTBI treatment.  
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 Table 7 summarizes individual predictors of treatment completion, while controlling for study 
group.  Age 40 years or older (ARR=1.384, 95% CI 1.124-1.704) and history of psychiatric 
hospitalizations or medications (ARR=0.548, 95% CI 0.297-1.012), were the only significant 
predictors of completion or non completion of treatment respectively.   
The reliability of constructed scales – social support, perceived benefits, and perceived barriers – 
was examined and all scales were found to be reliable; data is presented in Appendix 2, Table 1.  
None of the scales were found to be significant predictors.   
Of 16 knowledge items, correct answers on two were found to be significant predictors of 
improved completion, or showed a trend, in models with treatment group.  These items include: 
“you can get TB by kissing” (ARR=1.287, 95% CI 1.046-1.585) and “treatment of LTBI can 
take one month” (ARR=1.229, 95% CI 0.969-1.558).   
Factor analysis of the 14 attitudinal items in the questionnaire yielded 5 factors accounting for 
53.2 percent of the total variation (Appendix 2, Table 2 and Figure 1).  Final factor solution is 
shown in Appendix 2, Table 3.  Five scales were created but no reliable scales were found or 
retained (Appendix 2, Table 1).  The distribution of each attitudinal item was inspected carefully 
and depending on the distribution, the category with most responses was designated as the 
reference group or the two middle categories (‘agree’ and ‘disagree’) were collapsed and used as 
the reference group. When examining the 14 attitudinal items individually, two were found to be 
significant, or showed a trend, in models with treatment group.  Participants who strongly 
disagreed with the statement “you worry about passing the TB germ to loved ones,” were 
significantly more likely to complete than those who were more neutral (agree or disagree) 
(ARR=1.367, 95% CI 1.053-1.774).  Similarly, those who somewhat agreed with the statement 
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 “you believe you have the TB germ,” were significantly more likely to complete than those who 
strongly disagreed (ARR=1.459, 95% CI 1.032-2.064).  
All predictors significant at 0.10 or less were candidates for the multivariate model. While not 
significant on their own, foreign birth (ARR=1.056, 95% CI 0.843-1.322) and marriage 
(ARR=1.105, 95% CI 0.893-1.368) were further considered in multivariate models because of 
suspected interactions.  According to the multivariate model in Table 8, participants in both 
groups were equally likely to complete treatment (ARR=1.039, 95% CI 0.854-1.264).  Foreign 
birth (ARR=0.854, 95% CI 0.649-1.123) and marriage (ARR=0.508, 95% CI 0.258-0.998) were 
identified as predictors for non-completion of LTBI treatment; however, these factors were 
modified by interaction terms.  Unmarried foreign-born TB patients were less likely than U.S. 
born patients to complete treatment, while married foreign-born TB patients were substantially 
more likely than U.S. born patients to complete therapy (ARR=2.379, 95% CI 1.148-4.930).  
Age 40 or older was identified as a predictor of completion of treatment (ARR=1.303, 95% CI 
1.054-1.612) while history of mental illness (AOR=0.561, 95% CI 0.307-1.023) was identified 
as an additional predictor for non-completion of treatment. No knowledge or attitude items 
remained in the multivariate model.  Diagnostic statistics were used to assess the validity of the 
final model.  These diagnostic tests confirmed that the final model conforms to statistical 
assumptions for binomial regression. 
LTBI Adherence 
Some problems were noted by study staff regarding the MEMS being lost, expiring, or needing 
to be replaced due to damage.  But in general, results of the MEMS acceptability questionnaires 
indicate that the MEMS were used always or often by most participants (86%).  Additionally, 
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 participants reported that it was easy to understand how to use the cap (94%) and overall found 
using the cap to be easy (98%).  When self reported adherence was compared with data from the 
MEMS cap, good agreement (kappa=0.687) was found.  Where information did not match 
between the two methods, it was generally because MEMS adherence was lower than self 
reported adherence.  This suggests that when MEMS data was used for imputation, adherence 
may have been imputed at lower values than the self reported adherence.   
Models were run on 232 participants with 2,043 records of adherence: 1,257 (62%) of those were 
reported via interview, 589 (29%) were determined from chart and MEMS data, and 188 (9%) 
were imputed via the stochastic adherence algorithm.  Data for 18 participants could not be 
imputed following the imputation algorithm rules outlined above as no information was 
available.   
Figure 2a plots adherence by completion status over the duration of treatment based on a 
repeated measures model.  As expected, average adherence in the non-completers group is lower 
than in the completers group from the initiation of treatment and steadily drops from about 45% 
at month 1 to less than 5% by month 6.  Figure 2b plots adherence over time for individuals 
using spaghetti plots.  In the first couple of months of treatment, not much difference is evident 
in this plot between completers and non-completers; however, after the second month a big 
difference appears where non-completers do not adhere with the treatment.  These patterns are 
easier to detect with the heatmaps in Figure 2c, where each participant is represented by a layer 
instead of a line and intensity of the color is utilized to show the level of adherence.  It is clear 
from this plot that non-completers’ adherence decreased early in the treatment while completers 
had fairly steady levels of adherence throughout the treatment.  
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 Repeated measures analysis was conducted to compare adherence as a continuous–valued 
variable over the duration of the treatment and the final multivariate model is presented in Table 
9.  The repeated measures analysis potentially has more power for comparing the intervention 
and control groups.  In addition, a substantial difference in adherence rates was observed 
between study groups (9.7%).  For those who are in the intervention group, married, foreign-
born, 40 years or older, not homeless, not using alcohol, and correct on knowledge item “TST+ 
can mean need for medications,” expected adherence over time is 76%.   
The most common reasons reported for not adhering to treatment were “forgot”, “ran out of 
medications”, and “other priorities.”  Factor analysis of the 25 reasons for missing medications 
yielded 7 factors accounting for 56.0% of the total variation.  Some reasons did not load on any 
of the factors.  Therefore, the analysis was rerun excluding these variables so that the relative 
importance of each of the remaining items could be assessed.  Four factors including 17 variables 
emerged accounting for 53.7% of the total variation (Appendix 2, Table 4 and Figure 2).  Final 
factor solution is shown in Appendix 2, Table 5.  Four scales were created, three of which were 
determined to be reliable scales (Appendix 2, Table 1).  The first factor includes fears of side 
effects and harmful effects of the drugs as well as feeling good and a dislike of taking pills. The 
second factor includes reasons relating to current intoxication or planned alcohol use and general 
negative feelings about having to take the medications. The third factor includes the most 
common reason – simply forgot as well as other competing priorities such as work/family and 
pills not fitting in daily routine.  The last factor relates to running out of pills and problems with 
getting the medications.   
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 DISCUSSION  
Adherence to and completion of LTBI treatment are crucial factors in the effort to eliminate TB 
in the U.S. and are therefore of major public health relevance.  The two randomized controlled 
trials described above assessed an innovative peer support intervention for enhancing adherence 
to and completion of LTBI treatment among individuals in an urban setting in the U.S.  The 
inner city urban setting provided the opportunity to evaluate the impact of peer-led interventions 
to increase treatment completion rates in a disadvantaged population often faced with multiple 
barriers to adherence and completion of treatment for LTBI.  The interventions were 
multifaceted and addressed recognized barriers to adherence using an approach that could be 
replicated in other clinical settings. 
Participants in the Pathways intervention group were 1.5 times more likely to complete treatment 
compared with those in the control group, after controlling for other factors.  Despite this 
significant increase in the likelihood of completing LTBI treatment, the completion rate 
remained modest, with only 60% of participants in the Pathways intervention group completing 
LTBI treatment.  The rate of LTBI treatment completion in the control group is consistent with 
completion rates in this clinic population as well as in other populations.5  In TAPAS, LTBI 
treatment completion rates were similar in participants assigned to receive peer support and those 
assigned to the control group; however, study participants in both study arms of TAPAS had 
considerably higher treatment completion rates than non-study patients who initiated LTBI 
treatment in the same clinic, during the study period.     
MEMS monitoring was used for all TAPAS participants as an adherence measurement tool; it 
was not used in Pathways.  Apart from some minor changes in the clinic population (see Chapter 
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 3) and a more structured intervention based on a theoretical model in TAPAS, the use of MEMS 
was the only methodological difference between the studies.  Moreover, higher completion rates 
in TAPAS were present despite longer treatment duration, which has been associated in other 
studies with decreased adherence.4,38-40  While the MEMS were utilized in this study as a 
measurement tool to monitor adherence in all participants, it seems that there might have been an 
unintended intervention effect.  Researchers have acknowledged the unintended use of the 
MEMS as an adherence intervention.  The power for detecting an intervention effect was 
reduced by the higher than expected completion rate in the control group, which reduced the 
anticipated treatment effect from a 20 percentage point difference (based on Pathways results) to 
less than 5 percentage points.  An intervention effect for completing LTBI treatment was 
observed in both studies but it was statistically significant only in Pathways; however, the 
TAPAS intervention was found to be statistically significant for improving adherence.   
In the Pathways study, completion of high school, current homelessness, and agreement with two 
attitudinal items (“doctors don’t really care about curing your TB,” and “when you feel real bad, 
you would stay home instead of seeing the doctor,”) were found to be predictors for non-
completion of LTBI treatment after controlling for intervention group. 
In the TAPAS study, foreign birth, marriage, and history of mental illness were found to be 
predictors for non completion of LTBI treatment after controlling for intervention group; 
increased completion rates were found among married persons of foreign-birth.  Older age 
(defined as 40+ years old) was an additional predictor of improved treatment completion.  
Similar results were found in the adherence analysis regarding foreign birth, marriage, and older 
age.  Homelessness and current alcohol use were additional predictors of non adherence; 
understanding that a positive TST may mean the need for LTBI treatment was found to be a 
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 predictor of improved adherence.  In both studies, current homelessness was found to be a strong 
predictor of adherence to and completion of LTBI treatment. 
Adherence was assessed longitudinally over the course of treatment in both studies but could 
only be analyzed in the TAPAS study.  Prior studies found adherence in the first month of 
treatment to predict treatment completion.41-44  In a retrospective study in patients seen at an 
urban TB clinic, Parsyan et el. found that among those who failed to complete LTBI treatment, 
more than half (54%) defaulted during the first month of treatment.42  In another study, Sebastian 
et al. found that failure to attend the first appointment identified all defaulters43 and in an open-
label randomized trial comparing 4 months of RIF with 9 months of INH, the percent of doses 
taken and the variability of the interval between doses in the first month was found to be a highly 
significant predictor of LTBI treatment completion.41  This is similar to the findings in Trajman 
et al.’s multicenter study, where regularity of treatment and percentage of doses taken were 
found to be predictive of successful treatment completion.44  In the TAPAS study, we found that 
non-completers’ adherence decreased early in the treatment while completers had fairly steady 
levels of adherence throughout the treatment.  This finding suggests that it is important to 
intervene early in the treatment as the first two months of treatment are when patients tend to 
default treatment.  Identifying reasons for missing medications can suggest possible foci for 
interventions in the early months, such as weekly reminders to take the medications and ensuring 
that prescriptions are refilled on schedule.  
Pathways and TAPAS are unique in that they offer a systematic in-depth examination of TB 
knowledge and attitudes.  In Pathways, three knowledge items were found to be possible 
predictors of improved treatment completion but the relationship did not hold in multivariate 
modeling.  Similarly, in TAPAS, three knowledge items were found to be possible predictors of 
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 improved treatment completion but the relationship did not hold in multivariate modeling.  In 
Pathways, 10 attitudinal items were found to be significant, or showed a trend, in models with 
treatment group but only two remained significant in the multivariate models; in TAPAS, two 
were found to be significant, or showed a trend, in models with treatment group but the 
relationship did not hold in multivariate modeling.  This suggests that knowledge and attitudes 
may be less important than social factors in determining treatment completion.   
The randomized controlled design of the studies provided an opportunity to establish a causal 
link for the impact of the intervention between the independent variables and the treatment 
outcome.  There have been a limited number of studies that used a randomized controlled trial 
design to evaluate interventions to promote LTBI treatment completion.5  Furthermore, the few 
prior randomized controlled trials to date were conducted in specific high risk groups such as the 
homeless,14,45 drug users,13,46,47 and jail inmates.48  Our studies are not limited to a specific high 
risk group but instead to a general clinic population, albeit one at high risk of developing TB 
disease because of its location in an inner city urban setting where the risk for TB is greater.  
Using a clinic population offers generalizability of study findings to similar settings, which is an 
important issue in considering how the study may be able to inform public health practice.        
Limitations 
The main outcome variable, completion of treatment, was abstracted from medical charts; these 
data were typically not entered for study purposes, and therefore the quality of information 
obtained could not be verified through participant interview.  However, key variables such as 
treatment outcomes are submitted routinely to the Department of Health and are an integral part 
of the medical record; thus we can assume that they are reliable.  In addition, a few medical 
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 records could not be located; however, these participants were similarly distributed among the 
treatment groups.  To be conservative, it was assumed that a chart not found equals failure to 
complete.  Another possible limitation is that providers may not have been consistent in their 
determination of treatment completion; however, the small number of providers making this 
determination was blinded to their patients’ study status.  Self-reporting of some items (e.g., 
alcohol or drug use) may have been subject to social desirability bias in face-to-face interviews; 
however, this is a randomized controlled trial and most risk factors were balanced between the 
groups, as were Marlowe-Crowne scores measuring the tendency to present oneself in a socially 
desirable way.  Patients receiving DOT for LTBI were excluded from both studies; however, the 
DOT for LTBI population was found to be similar to the study population of Pathways49 and no 
changes in procedures for DOT referrals were implemented in the clinic during that period.  
Finally, this study was conducted in an inner city urban setting in the U.S. and the sample may 
reflect inner city populations but may not be representative of the general U.S. population.  
While our results cannot be rigorously generalized to the U.S. as a whole, they nonetheless have 
strong implications for the U.S. population. 
 
CONCLUSIONS 
The design of the two studies, Pathways and TAPAS, provided an opportunity to evaluate an 
innovative peer support intervention to increase LTBI treatment completion rates in an inner city 
urban setting in the U.S.  The peer support intervention was found to be associated with 
significant increase in LTBI treatment completion rates in the Pathways population but not in the 
TAPAS population, whereas completion rates increased in the control group as well as in the 
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 intervention group in the latter study.  The power for detecting an intervention effect in TAPAS 
was reduced by the higher than expected completion rates in both groups; however, the effect of 
the TAPAS intervention is statistically significant in the adherence model.  Adherence analysis 
in TAPAS suggests that it is important to intervene with more tangible support early in the 
treatment as the first two months of treatment present a danger period where patients tend to 
default treatment.  Identifying reasons for missing medications can suggest possible foci for 
interventions in the early months, such as weekly reminders to take the medications and ensuring 
that prescriptions are refilled on schedule.   
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Figures 
Figure 1a: Pathways Study Participant Flow 
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  Figure 1b: TAPAS Study Participant Flow 
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Table 1: Baseline Characteristics of Participants in the Pathways Study 







 N % N % N %  
Age <40 203 56.39 98 55.37 105 57.38 0.7007 






























Ever homeless 138 38.33 51 28.81 87 47.54 0.0003 
Homeless past yr 92 25.63 33 18.75 59 32.24 0.0034 
Married/Common-law 93 25.91 48 27.27 45 24.59 0.5619 
Foreign-born 172 47.78 93 52.54 79 43.17 0.0751 
Completed high school 183 53.82 93 55.69 90 52.02 0.4979 
Unemployed 262 72.78 124 70.06 138 75.41 0.2539 
Prior LTBI tx 49 13.61 26 14.69 23 12.57 0.5574 
Emotional/psych 
hospitalizations 
28 7.84 13 7.43 15 8.24 0.7751 
HIV infected 17 4.72 10 5.65 7 3.83 0.3486 
Currently smoke 170 47.22 83 46.89 87 47.54 0.9020 
Ever drink alcohol 248 70.45 119 69.59 129 71.27 0.7299 
Currently drink 
alcohol 
117 32.50 60 33.90 57 31.15 0.5775 
Ever drug use 211 58.61 93 52.54 118 64.48 0.0215 
Currently use drugs 80 22.22 31 17.51 49 26.78 0.0346 
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Risk Ratio 95% CI p-value 

















1.561 1.255-1.942 <0.0001 
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95% CI p-value 
Demographics      
Age 40+ years -0.1091 0.1026 0.8966 0.7333-1.0963 0.2875 
Male -0.1426 0.1022 0.8671 0.7097-1.0593 0.1626 
Race/Ethnicity      
   Latino vs. Black -0.0603 0.1265 0.9415 0.7348-1.2062 0.6334 
   Other vs. Black -0.0668 0.2093 0.9354 0.6206-1.4097 0.7495 
Foreign-born 0.0474 0.1042 1.0486 0.8549-1.2861 0.6489 
Social Characteristics      
Completed high school -0.2465 0.1033 0.7816 0.6383-0.9570 0.0171 
Employed -0.0844 0.1180 0.9190 0.7293-1.1582 0.4743 
Married 0.0816 0.1116 1.0850 0.8718-1.3503 0.4649 
Ever homeless -0.1855 0.1173 0.8307 0.6601-1.0454 0.1138 
Currently homeless -0.3622 0.1523 0.6961 0.5164-0.9384 0.0174 
HIV infected 0.1305 0.0974 1.1394 0.9415-1.3790 0.1800 
Life stressors – 2 or more -0.0617 0.1038 0.9402 0.7671-1.1522 0.5521 
Substance Use      
Current smoking -0.2365 0.1060 0.7894 0.6412-0.9717 0.0257 
Ever alcohol use -0.0653 0.1125 0.9368 0.7514-1.1679 0.5616 
Current alcohol use 0.0270 0.1089 1.0273 0.8298-1.2719 0.8045 
Ever drug use -0.2172 0.1037 0.8048 0.6567-0.9863 0.0363 
Current drug use -0.2355 0.1486 0.7901 0.5905-1.0573 0.1130 
Social Support      
There are people who make you feel liked or loved 0.0749 0.1326 1.0778 0.8312-1.3975 0.5721 
There are people you feel you can talk to about 
personal or private matters 
0.2219 0.0955 1.2484 1.0353-1.5055 0.0202 
There are people who come to you when they need 
help 
0.0329 0.1001 1.0335 0.8494-1.2575 0.7423 
If needed immediate help, had people who would help 0.0801 0.0927 1.0834 0.9035-1.2992 0.3873 
If needed help getting things done, had people who 
would help 
0.1298 0.0934 1.1386 0.9481-1.3675 0.1647 
There are other people who give you information 
about services need 
-0.0238 0.0748 0.9765 0.8433-1.1307 0.7503 
Knowledge- Transmission      
K1 – by breathing air with TB 0.3314 0.2456 1.3929 0.8608-2.2539 0.1772 
K2 – by having sex without condom -0.1195 0.1050 0.8874 0.7223-1.0901 0.2551 
K3 – by living in crowded conditions 0.3576 0.2694 1.4299 0.8434-2.4243 0.1843 
K4 – by eating food prepared  0.0014 0.1045 1.0014 0.8159-1.2291 0.9895 
K5 – through kissing -0.0093 0.1235 0.9908 0.7778-1.2621 0.9402 
K6 – by sharing dishes or bottle -0.1671 0.1111 0.8461 0.6806-1.0519 0.1324 
Knowledge - Symptoms      
K7a – losing weight 0.0092 0.1154 1.0093 0.8050-1.2653 0.9363 
K7b – coughing 0.3432 0.2538 1.4094 0.8571-2.3177 0.1763 
K7c – vomiting 0.0006 0.1142 1.0006 0.7999-1.2517 0.9956 
K7d – losing hair 0.0449 0.1062 1.0459 0.8494-1.2879 0.6725 
K7e – coughing up blood 0.0758 0.1351 1.0787 0.8278-1.4056 0.5747 
Knowledge – Testing      
K8 – TST is vaccination against TB -0.2081 0.1026 0.8121 0.6642-0.9930 0.0425 
K9 – CXR can tell if sick with TB -0.1178 0.2279 0.8889 0.5687-1.3894 0.6053 
K10 – TST+ means already sick with TB -0.0344 0.1087 0.9662 0.7808-1.9555 0.7514 
K11 – CXR can tell if have DR TB -0.1829 0.1213 0.8328 0.6566-1.0564 0.1316 
K12 – family doesn’t need to be checked -0.0840 0.1188 0.9194 0.7284-1.1605 0.4795 
K13 – TST+ can give TB to others 0.0176 0.1043 1.0177 0.8295-1.2486 0.8664 
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95% CI p-value 
Knowledge – Treatment      
K14 – most cases can be cured by meds 0.1191 0.2415 1.1265 0.7017-1.8083 0.6219 
K15 – HIV+ more likely to get TB -0.2060 0.1123 0.8138 0.6531-1.0141 0.0665 
K16 – okay to stop meds once feel better -0.0847 0.1620 0.9188 0.6688-1.2621 0.6010 
K17 – patients can be ordered to take meds -0.0525 0.1059 0.9489 0.7710-1.1678 0.6202 
K18 – TST+ may need to take meds -0.3495 0.1250 0.7050 0.5519-0.9007 0.0052 
K19 – may get rash from TB meds -0.1534 0.1026 0.8578 0.7015-1.0489 0.1349 
K20 – treatment can be completed in 1 month -0.0813 0.1311 0.9220 0.7130-1.1921 0.5354 
Knowledge Score -0.0192 0.0146 0.9809 0.9532-1.0095 0.1884 
Attitudes      
K22 – TB is disease you have to take seriously -0.0237 0.1275 0.9766 0.7607-1.2537 0.8524 
K23 – if someone gets TB, it is their own fault 0.0929 0.0591 1.0974 0.9773-1.2322 0.1161 
K24 – taking TB medications is important -0.1668 0.0886 0.8464 0.7114-1.0069 0.0598 
K25 – TB is something you and friends talk about -0.0537 0.0443 0.9477 0.8689-1.0337 0.2256 
K26 – would continue treatment even if had to pay -0.0778 0.0544 0.9251 0.8316-1.0291 0.1523 
K27 – know better than the doctor when best to stop 
medications 
-0.0436 0.0833 0.9573 0.8131-1.1272 0.6010 
K28 – not embarrassed to tell people have TB     0.0967 
   Strongly agree -0.2857 0.1288 0.7515 0.5839-0.9672 0.0265 
   Strongly disagree -0.1253 0.1168 0.8822 0.7017-1.1090 0.2830 
   Disagree/agree Ref     
K29 – not important to keep appointments     0.2033 
   Strongly agree -0.2366 0.2219 0.7893 0.5109-1.2195 0.2864 
   Strongly disagree -0.3397 0.1523 0.7120 0.5283-0.9596 0.0257 
   Disagree/agree Ref     
K30 – medications today powerful in fighting TB -0.0675 0.0752 0.9347 0.8066-1.0831 0.3692 
K31 – family/friends don’t care if keep app’ts/meds -0.1188 0.0706 0.8880 0.7732-1.0199 0.0927 
K32 – since word spread about TB, people avoid you -0.0589 0.0654 0.9428 0.8294-1.0717 0.3676 
K33 – takes something bad to not take medications     0.8989 
   Strongly agree 0.0489 0.1478 1.0501 0.7861-1.4028 0.7407 
   Strongly disagree -0.0315 0.1793 0.9690 0.6818-1.3771 0.8606 
   Disagree/agree Ref     
K34 – appointments more trouble than worth 0.0811 0.0578 1.0845 0.9684-1.2145 0.1601 
K35 – usually follow doctor’s advice 0.0425 0.1000 1.0435 0.8577-1.2695 0.6706 
K36 – as hard as you try, you are going to miss some 
of your medications 
    0.0266 
   Strongly agree -0.5845 0.2275 0.5574 0.3568-0.8707 0.0102 
   Strongly disagree -0.2058 0.1030 0.8140 0.6652-0.9962 0.0458 
   Disagree/agree Ref     
K37 – doctors don’t really care about curing TB     0.0398 
   Strongly agree -1.0254 0.4621 0.3587 0.1450-0.8872 0.0265 
   Strongly disagree -0.1588 0.1395 0.8532 0.6490-1.1214 0.2550 
   Disagree/agree Ref     
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95% CI p-value 
K38 – care about what family/friends think of treatment     0.0266 
   Strongly agree -0.2921 0.1206 0.7467 0.5895-0.9458 0.0154 
   Strongly disagree -0.1305 0.1232 0.8777 0.6894-1.1175 0.2898 
   Disagree/agree Ref     
K39 – taking TB meds is a hassle     0.0270 
   Strongly agree -0.8392 0.4472 0.4321 0.1798-1.0380 0.0606 
   Strongly disagree -0.2336 0.1164 0.7917 0.6301-0.9946 0.0448 
   Disagree/agree Ref     
K40 – when feel real bad, stay home instead of seeing dr      0.0186 
   Strongly agree -0.7338 0.3104 0.4801 0.2613-0.8821 0.0181 
   Strongly disagree -0.1793 0.1083 0.8359 0.6760-1.0336 0.0978 
   Disagree/agree Ref     
K41 – family is ashamed have TB -0.1292 0.0907 0.8788 0.7357-1.0498 0.1543 
K42 – if feel worse taking meds, would stop taking it -0.0056 0.0411 0.9944 0.9175-1.0778 0.8916 
K43 – doctors know how to treat TB -0.0264 0.0866 0.9739 0.8218-1.1541 0.7602 
K44 – believe have the TB germ     0.0494 
   Strongly agree -0.2604 0.1122 0.7707 0.6186-0.9604 0.0204 
   Strongly disagree -0.2841 0.1437 0.7527 0.5679-0.9975 0.0480 
   Disagree/agree Ref     
K45 – will not get sick with TB because lucky -0.0008 0.0473 0.9992 0.9107-1.0964 0.9873 
K46 – no matter what you do, can still get TB     0.0484 
   Strongly agree -0.2919 0.1142 0.7468 0.5971-0.9342 0.0106 
   Strongly disagree -0.1158 0.1354 0.8907 0.6830-1.1614 0.3925 
   Disagree/agree Ref     
K47 – if do right think, can avoid getting TB 0.0007 0.0436 1.0007 0.9186-1.0900 0.9880 
RR = Risk Ratio   
CI = Confidence Interval 
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Intervention group 0.4084 0.1109 1.5043 1.2106-1.8694 0.0002 
High school -0.2235 0.1010 0.7997 0.6561-0.9748 0.0269 
Currently homeless -0.2399 0.1558 0.7867 0.5796-1.0678 0.1237 
K37 – Doctors don’t really care about 
curing your TB 
     
   Strongly agree -0.8191 0.4500 0.4408 0.1825-1.0648 0.0687 
   Strongly disagree -0.1588 0.1303 0.8532 0.6609-1.1014 0.2229 
   Disagree/agree Ref     
K40 – when you feel really bad, you would 
stay home instead of seeing the doctor 
     
   Strongly agree -0.7117 0.3292 0.4908 0.2574-0.9358 0.0306 
   Strongly disagree -0.0923 0.1056 0.9118 0.7414-1.1214 0.3818 
   Disagree/agree Ref     
RR = Risk Ratio   





 Table 5: Baseline Characteristics of Participants in the TAPAS Study (N=250) 
 







 N % N % N %  
Age <40 134 53.6 71 55.5 63 51.6 0.5439 






































Ever homeless 83 33.3 44 34.7 39 32.0 0.6540 
Homeless past yr 40 16.1 21 16.5 19 15.6 0.8363 
Married/Common-law 97 38.8 51 39.8 46 37.7 0.7287 
Foreign-born 167 66.8 86 67.2 81 66.4 0.8940 
Completed high school 153 61.2 78 60.9 75 61.5 0.9305 
Unemployed 147 58.8 76 59.4 71 58.2 0.8499 
Prior LTBI tx 15 6.1 7 5.5 8 6.6 0.7165 
Any psychiatric history 21 8.4 11 8.6 10 8.2 0.9099 
Currently smoke 84 33.6 46 35.9 38 31.2 0.4229 
Ever drink alcohol 179 71.6 94 73.4 85 69.7 0.5093 
Currently drink alcohol 80 32.0 38 29.7 42 34.4 0.4220 
Ever drug use 129 51.6 69 53.9 60 49.2 0.4548 
Currently use drugs 40 16.0 20 15.6 20 16.4 0.8684 
Depressed by CESD16 86 34.4 48 37.5 38 31.2 0.2906 
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95% CI p-value 





















 Table 7: TAPAS binomial regression analysis of predictors of completion of care, controlling for randomization group 










Demographics      
Age 40+ years 0.3247 0.1061 1.3837 1.1238-1.7036 0.0022 
Male -0.0512 0.1186 0.9501 0.7529-1.1988 0.6660 
Race/Ethnicity     0.1790 
  African-American vs. African -0.1468 0.1190 0.8635 0.6838-1.0904 0.2174 
  Latino vs. African -0.3449 0.1692 0.7083 0.5084-0.9868 0.0415 
  Other vs. African -0.0814 0.1826 0.9218 0.6445-1.3185 0.6558 
Foreign-born 0.0541 0.1149 1.0556 0.8428-1.3221 0.6374 
Social Characteristics      
Completed high school -0.1249 0.1062 0.8826 0.7168-1.0867 0.2393 
Employed 0.0897 0.1059 1.0939 0.8888-1.3462 0.3969 
Married 0.0999 0.1088 1.1051 0.8929-1.3678 0.3584 
Ever homeless -0.0804 0.1168 0.9227 0.7339-1.1602 0.4913 
Currently homeless -0.1877 0.1676 0.8288 0.5968-1.1511 0.2626 
Prior TB -0.1042 0.2474 0.9010 0.5549-1.4632 0.6736 
Any psychiatric history (hospitalization or 
meds) 
-0.6013 0.3131 0.5481 0.2967-1.0124 0.0548 
Depressed by CESD>16 0.0478 0.1096 1.0489 0.8462-1.3002 0.6630 
Substance Use      
Current smoking -0.0185 0.1127 0.9817 0.7871-1.2244 0.8699 
Ever alcohol use -0.1675 0.1075 0.8458 0.6851-1.0442 0.1192 
Current alcohol use -0.1559 0.1227 0.8556 0.6727-1.0883 0.2040 
Ever drug use 0.0003 0.1058 1.0003 0.8130-1.2309 0.9974 
Current drug use -0.1958 0.1675 0.8222 0.5921-1.1416 0.2423 
Benefits and barriers      
Benefits scale 0.0386 0.1237 1.0394 0.8157-1.3244 0.7548 
Barriers scale -0.1704 0.1484 0.8433 0.6305-1.1280 0.2509 
Quality of life – physical (mean) -0.0034 0.0060 0.9966 0.9850-1.0083 0.5690 
Quality of life - mental (mean) 0.0056 0.0051 1.0056 0.9956-1.0157 0.2731 
Social Support scale -0.0085 0.0560 0.9916 0.8886-1.1065 0.8800 
Knowledge- Transmission      
ka1 TB from crowded conditions 0.0986 0.1894 1.1036 0.7613-1.5998 0.6029 
ka2 TB from sharing dishes etc. 0.1014 0.1161 1.1067 0.8814-1.3895 0.3826 
ka3 TB through kissing 0.2526 0.1061 1.2874 1.0457-1.5849 0.0173 
ka4 TB from stranger vs family 0.0526 0.1058 1.0540 0.8567-1.2968 0.6190 
Knowledge – Testing/Treatment      
ka5 TST+ means have disease -0.1315 0.1081 0.8768 0.7093-1.0837 0.2238 
ka6 sleeping TB is contagious 0.1485 0.1103 1.1601 0.9345-1.4402 0.1783 
ka7 TST+ can mean need for meds 0.6988 0.4857 2.0113 0.7763-5.2108 0.1502 
ka8 most TB can be cured with meds 0.2275 0.2826 1.2554 0.7215-2.1845 0.4209 
ka9 HIV+ means more likely to get TB -0.1380 0.1070 0.8711 0.7063-1.0742 0.1969 
ka10 TLTBI can take 1 month 0.2060 0.1210 1.2287 0.9692-1.5577 0.0888 
ka11 undocumented person can be deported for 
TB treatment 
0.0185 0.1086 1.0187 0.8234-1.2603 0.8645 
Knowledge – Symptoms      
ka12 – losing weight 0.1869 0.1713 1.2055 0.8617-1.6864 0.2753 
ka13 – swollen feet -0.1739 0.1159 0.8404 0.6695-1.0547 0.1336 
ka14 – coughing 0.2686 0.3779 1.3081 0.6237-2.7438 0.4773 
ka15 – vomiting 0.0090 0.1142 1.0090 0.8067-1.2620 0.9375 
ka16 – coughing up blood 0.0567 0.1585 1.0584 0.7757-1.4440 0.7205 
Knowledge Score 0.0451 0.0292 1.0461 0.9878-1.1078 0.1231 
RR = Risk Ratio; CI = Confidence Interval 
  
150
 Table 7: TAPAS binomial regression analysis of predictors of completion of care, controlling for randomization group 










Attitudes      
ka17 BCG vaccine prevents TB disease 0.0313 0.0541 1.0318 0.9280-1.1472 0.5633 
ka18 no matter what could still get TB germ     0.1137 
   Somewhat agree -0.0127 0.1378 0.9874 0.7537-1.2934 0.9265 
   Somewhat disagree 0.0809 0.1380 1.0843 0.8272-1.4212 0.5578 
   Strongly agree -0.2876 0.1589 0.7501 0.5493-1.0241 0.0703 
   Strongly disagree Ref     
ka19 taking TB meds is important 0.2409 0.1852 1.2723 0.8851-1.8290 0.1933 
ka20 you know better than doctor when to stop 
meds 
-0.0174 0.0552 0.9828 0.8819-1.0951 0.7530 
ka21 clinic appt’s are more trouble than worth -0.0158 0.0726 0.9843 0.8537-1.1349 0.8278 
ka22 do not trust doctor for best care     0.3364 
   Strongly agree -0.1216 0.3272 0.8855 0.4663-1.6814 0.7101 
   Strongly disagree 0.1601 0.1444 1.1736 0.8844-1.5574 0.2675 
   Disagree/agree Ref     
ka23 do right thing can avoid getting TB      0.1757 
   Strongly agree 0.2654 0.1450 1.3040 0.9814-1.7326 0.0672 
   Strongly disagree 0.1650 0.2211 1.1794 0.7647-1.8190 0.4554 
   Disagree/agree Ref     
ka24 worry about passing TB germ to loved 
ones 
    0.0753 
   Strongly agree 0.0665 0.1289 1.0688 0.8302-1.3759 0.6058 
   Strongly disagree 0.3124 0.1330 1.3667 1.0531-1.7739 0.0189 
   Disagree/agree Ref     
ka25 embarrassed to tell you have TB germ     0.6854 
   Strongly agree -0.0485 0.1408 0.9527 0.7229-1.2555 0.7304 
   Strongly disagree -0.0904 0.1200 0.9136 0.7221-1.1558 0.4512 
   Disagree/agree Ref     
ka26 believe that you have the TB germ     0.0728 
   Somewhat agree 0.3780 0.1768 1.4594 1.0319-2.0639 0.0325 
   Somewhat disagree 0.0098 0.2576 1.0098 0.5884-1.7333 0.9715 
   Strongly agree 0.1559 0.1791 1.1687 0.8228-1.6601 0.3839 
   Strongly disagree Ref     
ka27 care about what family and friends think of 
TB treatment 
    0.9674 
   Strongly agree 0.0401 0.1243 1.0409 0.8158-1.3282 0.7472 
   Strongly disagree 0.0160 0.1368 1.0161 0.7771-1.3287 0.9069 
   Disagree/agree Ref     
ka28 try hard, will still miss some meds     0.8239 
   Somewhat agree 0.0887 0.1202 1.0928 0.8635-1.3829 0.4603 
   Somewhat disagree -0.0315 0.1564 0.9690 0.7132-1.3167 0.8406 
   Strongly agree -0.0804 0.2421 0.9227 0.5741-1.4830 0.7397 
   Strongly disagree Ref     
ka29 taking TB meds is a hassle     0.2019 
   Strongly agree 0.4126 0.1645 1.5107 1.0944-2.0855 0.0121 
   Strongly disagree 0.1033 0.1247 1.1088 0.8684-1.4158 0.4073 
   Disagree/agree Ref     
ka30 only something really bad would prevent 
from taking TB meds 
    0.9460 
   Strongly agree 0.0483 0.1302 1.0495 0.8131-1.3546 0.7108 
   Strongly disagree 0.0518 0.1341 1.0532 0.8097-1.3698 0.6994 
   Disagree/agree Ref     
RR = Risk Ratio; CI = Confidence Interval 
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Intervention 0.0380 0.1000 1.0387 0.8538-1.2636 0.7043 
Married -0.6778 0.3447 0.5077 0.2584-0.9977 0.0492 
Foreign-born -0.1581 0.1399 0.8537 0.6490-1.1231 0.2584 
Married and Foreign-born 0.8666 0.3718 2.3787 1.1477-4.9302 0.0198 
Age 40+ 0.2649 0.1085 1.3033 1.0536-1.6121 0.0146 
Psychiatric history -0.5788 0.3068 0.5606 0.3072-1.0228 0.0592 
 
RR = Risk Ratio   




 Table 9: TAPAS Predictors of treatment adherence over time by repeated measures analysis 
 Estimate Standard  
error 
t-value p-value 
Base adherence level 15.8189 14.9026 1.06 0.2896 
Intervention group 9.7063 4.7684 2.04 0.0430 
Married -15.1533 9.8339 -1.54 0.6430 
Foreign-born -6.9232 6.5853 -1.05 0.3421 
Married and foreign-born 24.9865 11.6543 2.14 0.0331 
Age 40+ 16.8777 5.0227 3.36 0.0009 
Currently homeless -15.2774 6.8059 -2.24 0.0258 
Current alcohol use -10.4141 5.1117 -2.04 0.0428 
Correct on TST+ can mean need for 
medications 




 Chapter 6 
Dissertation Summary and General Discussion 
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 DISSERTATION GOALS 
The objectives of this dissertation were 1) to critically review the literature on adherence to 
treatment of LTBI, 2) To identify the change in demographic, social, and behavioral 
characteristics of patients undergoing treatment for LTBI in the Chest Clinic at Harlem Hospital 
between 1996 and 2005, 3) to identify patient demographic, social, and behavioral characteristics 
that are associated with LTBI treatment completion, and 4) to assess the impact of a peer-based 
experimental intervention on adherence to and completion of LTBI treatment in a general clinic 
population in an urban setting in the U.S.  This was achieved by using data from the Pathways to 
Completion Study (recruitment from 1996 through 2000) as well as data from the Tuberculosis 
Adherence Partnership Alliance Study (TAPAS ) (recruitment from 2002 through 2005).  
Pathways and TAPAS were two sequential NIH-funded randomized controlled trials designed to 
compare an experimental peer-based intervention to standard of care for ensuring completion of 
treatment for LTBI in an inner city urban setting.   
 
SUMMARY OF FINDINGS 
Chapter 2 of the dissertation reviews the literature on adherence to treatment of LTBI.  Chapter 3 
provides an in-depth look at the specific urban population that was included in this dissertation.  
Chapter 4 examines factors that are associated with completion of LTBI treatment.  Chapter 5 
evaluates the effects of an experimental peer support intervention on adherence and completion 
of LTBI treatment.  
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 In reviewing the LTBI adherence literature we found that consistently employing tools for 
measuring and improving adherence is fundamental.  Identifying barriers to adherence and 
treatment completion will facilitate the development of effective, appropriate interventions.  A 
‘one-size-fits-all’ approach to LTBI treatment adherence is not likely to succeed across all 
settings.  Innovative approaches can inspire future interventions and suggest solutions for the 
current problems facing LTBI programs and their patients. 
An examination of the change in demographic, social, and behavioral characteristics of patients 
undergoing treatment for LTBI in the Chest Clinic at Harlem Hospital between 1996 and 2005 
found that the cohort of participants receiving treatment for LTBI in Harlem between 2002 and 
2005 tend to have higher levels of foreign-birth and marriage, and lower levels of homelessness 
and unemployment, less experience with prior LTBI treatment, and lower rates of smoking and 
drug use than patients in the late 1990s.  The 2002-2005 participants undergoing treatment for 
LTBI mirror the NYC and national TB picture in terms of gender, age, and foreign birth; 
however, the racial distribution is different as the Harlem community does not have a large 
population of Asians. 
In these studies of LTBI treatment in an inner city urban population, homelessness, foreign birth, 
alcohol use, and marriage predicted success at completing LTBI treatment.  Special efforts to 
reach patient groups identified with these factors have the potential to improve completion rates.  
Our findings suggest that tangible assistance would be more effective than educational 
interventions, which are currently the primary strategy used to improve LTBI treatment 
completion.  
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 The peer support experimental intervention was found to be very effective in the Pathways 
population but not in the TAPAS population where completion rates increased substantially for 
both the intervention and control groups.  The power for detecting an intervention effect in 
TAPAS was reduced by the higher than expected completion rates in both groups; however, the 
effect of the TAPAS intervention is statistically significant in the adherence model.  Adherence 
analysis in TAPAS suggests that it is important to intervene early in the treatment when patients 
tend to default treatment.  Close follow-up of patients during the first two months of treatment, 
with prompt intervention to encourage completion among those stopping treatment may yield 
better outcomes and reduce costs over the long term. 
 
STRENGTHS AND LIMITATIONS 
The design and analysis of this dissertation involved multiple strengths as well as potential 
limitations that must be considered for drawing inferences regarding the findings.  Among the 
strengths are the inner city urban setting and the prospective nature of both studies, which 
afforded an opportunity to establish causal relationships in a general clinic population as well as 
offered some generalizability to the findings.  Moreover, adherence to and completion of LTBI 
treatment are crucial factors in the effort to eliminate TB in the U.S. and are therefore of major 
public health relevance.  The potential or actual limitations of the study include the abstraction of 
key variables from medical charts, the inability to locate a small number of medical records, and 
reduced statistical power for TAPAS analyses due to higher than expected completion rates in 
both groups.   
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 Limitations of the study 
The main outcome variable, completion of treatment, was abstracted from medical charts; these 
data were typically not entered for study purposes, and therefore the quality of information 
obtained could not be verified through participant interview.  However, key variables such as 
treatment outcomes are submitted routinely to the Department of Health and are an integral part 
of the medical record; thus we can assume that they are reliable.  In addition, a small number of 
medical records could not be located; however, these participants were similarly distributed 
among the treatment groups.  To be conservative, it was assumed that a chart not found equals 
failure to complete.   
An accurate measurement of adherence is very challenging.  While every effort was made to 
carefully and correctly assess adherence, it is not certain that measurement error was not 
introduced.  This was especially problematic as the degree of missing or incomplete adherence 
data in TAPAS was fairly high.  However, a very structured approach for imputation was 
developed and utilized.  Final models were run on the partial as well as total sample (including 
imputed data) and results did not vary. 
Both studies were designed to have adequate sample sizes that allow for sufficient power to test 
the proposed hypotheses; however, the power for detecting an intervention effect in TAPAS was 
reduced by the higher than expected completion rates in both groups.  An intervention effect for 
completing LTBI treatment was observed in both studies but it was statistically significant only 
in Pathways; however, the effect of the TAPAS intervention is statistically significant in the 
adherence model.   
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 The Pathways study collected self-reported HIV status at baseline but the TAPAS study did not 
collect that information.  Considering the risk associated with HIV infection in progression from 
latent infection to active disease, and the possible impact of HIV status on perceived severity and 
susceptibility, this information is important.  It was not possible to collect HIV information for 
the TAPAS population for this analysis.  The predictors analysis in Chapter 4 was based on a 
combined sample of control patients from both studies, which means that self-reported HIV 
status could not be used as a predictor in this analysis.  The interventions analysis in Chapter 5 
was based on separate analyses for each study; therefore, self-reported HIV status was tested in 
the Pathways analysis and was not found to be a predictor of treatment completion.   
Strengths of the study 
The inner city urban setting provided a valuable opportunity to examine predictors of adherence 
to and completion of LTBI treatment in a clinic population where patients are at great risk of 
getting TB and face many barriers to the completion of treatment.  Additionally, the prospective 
nature of both studies allowed us to establish a temporal relationship for the predictors study and 
establish a causal link for the impact of the peer-based interventions between the independent 
variables and the treatment outcome in this disadvantaged population.  Comparing and 
contrasting two patient populations enrolled in two separate RCTs added richness to the 
analyses.     
Adherence measurement plays an important role in assessing patient outcomes.  While there is 
no single universally preferred measure of adherence, several measures provide valuable, if 
partial, information.  A combination of indirect assessment like self-report with a direct measure 
like record of clinic attendance is considered the current “state-of-the-art” in measurement of 
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 adherence behavior.  Furthermore, the self report and clinic record are informative, easy to use 
and replicate, and are not too costly or cumbersome for this patient population.  Both studies 
used these methods.  The TAPAS study adopted an additional method, electronic monitoring 
devices to record prescription bottle openings.     
The generalizability of study findings is an important issue in considering how the study may be 
able to inform public health practice.  Our studies are not limited to a specific high risk group but 
instead to a general clinic population, albeit one at high risk of developing TB disease because of 
its location in an inner city urban setting where the risk for TB is greater.  Using a clinic 
population offers generalizability of study findings, which is an important issue in considering 
how the study may be able to inform public health practice.       
Adherence to and completion of LTBI treatment are crucial factors in the effort to eliminate TB 
in the U.S. and are therefore of major public health relevance.  The findings from this study 
contribute to our understanding of barriers and facilitators associated with adherence and 
completion of LTBI treatment and the effectiveness of a peer-led intervention for improving 
adherence to and completion of LTBI treatment.  This understanding facilitates the development 
of effective, culturally relevant interventions.               
 
FUTURE RESEARCH DIRECTIONS 
Our findings point to several questions requiring further discussion and investigation in future 
research studies.  Recent work has shown the importance of shortened LTBI treatment regimens 
for ensuring treatment completion.1  A recent study found completion rates ranging from 71.6% 
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 to 91.4% with four months of rifampin.2  Some of the newer shorter regimens have intermittent 
dosing, which present new challenges that will need to be explored. Further research is required 
to determine whether factors found to predict completion would remain effective predictors 
among patients on shortened regimens characterized by higher completion rates. 
Adherence analysis in TAPAS suggests that it is important to intervene early in the treatment 
course as the first two months of treatment present a danger period where patients tend to default 
treatment.  Developing and testing interventions that focus on the early part of the treatment is 
imperative.  Examples of such interventions are daily reminders to take the medications by 
utilizing cell phone technology (such as text messages or interactive voice response) and 
pharmacy linkages to ensure that prescriptions are refilled on schedule.  Another intervention 
that needs to be evaluated is the use of wireless medication bottles that transmit a signal when 
opened, providing an opportunity to intervene in real time.  Because adherence is dynamic and 
declines either gradually (such as from pill fatigue) or suddenly (from family emergencies), real-
time monitoring represents a shift from reactive responses to proactive interventions designed to 
prevent treatment failure.  Close follow-up of patients during the first two months of treatment, 
with prompt intervention to encourage completion among those stopping treatment, may yield 




1. Horsburgh CR, Goldberg S, Bethel J, et al. Latent tuberculosis infection treatment 
acceptance and completion in the United States and Canada. Chest 2010;137:401-9. 
2. Ziakas P, Mylonakis E. 4 months of rifampin compared with 9 months of isoniazid for 
the management of latent tuberculosis infection: a meta-analysis and cost-effectiveness 








Appendix 1 Table 1: Reliability scores for TB attitudes scales 
 # Items in factor Cronbach’s alpha 
Social support 6 0.475 
Attitudes Factor 1 3 0.474 
Attitudes Factor 2 3 0.322 
Attitudes Factor 3 2 0.578 
Attitudes Factor 4 3 0.273 
Attitudes Factor 5 2 0.292 
Attitudes Factor 6 2 0.278 




 Appendix 1 Table 2: TB Attitudes Number of Factors and Variance Explained 
Total Variance Explained 
Compon
ent 
Initial Eigenvalues Extraction Sums of Squared Loadings 
















1 2.105 12.380 12.380 2.105 12.380 12.380 1.586 9.329 9.329 
2 1.651 9.710 22.090 1.651 9.710 22.090 1.528 8.986 18.315 
3 1.421 8.357 30.446 1.421 8.357 30.446 1.522 8.952 27.267 
4 1.338 7.871 38.317 1.338 7.871 38.317 1.419 8.346 35.612 
5 1.179 6.935 45.252 1.179 6.935 45.252 1.254 7.377 42.989 
6 1.071 6.298 51.550 1.071 6.298 51.550 1.252 7.362 50.351 
7 1.032 6.072 57.623 1.032 6.072 57.623 1.236 7.271 57.623 
8 .933 5.489 63.112       
9 .896 5.273 68.385       
10 .886 5.213 73.598       
11 .802 4.718 78.316       
12 .733 4.311 82.627       
13 .671 3.946 86.572       
14 .652 3.833 90.406       
15 .626 3.682 94.088       
16 .578 3.400 97.488       
17 .427 2.512 100.000       




























k43-Drs know how to treat TB .685       
k30-Meds today are very powerful in fighting TB .614       
k35-You usually follow doctors advice .612       
k24-Taking TB medicine is important  .737      
k22-TB is disease have to take seriously  .608      
k44-You believe that you have TB germ  .587      
k41-Family is ashamed that you have TB   .808     
k32-Since word has spread that have TB, people avoid you   .802     
k27-You know better that the Dr when to stop meds    .728    
k29-Not important to keep your appointments    .631    
k33-It takes something really bad to not take meds    -.537    
k40-When you feel really bad, stay home instead seeing Dr     .758   
k42-If feel worse when taking meds, would stop taking it     .580   
k38-You care about what family/friends think of tb treatment      -.714  
k31-Family and friends do not care if keep appointments      .714  
k45-Will not get TB b/c you are lucky       .725 











Appendix 2 Table 1: Reliability scores for all scales 
 
 # Items in factor Cronbach’s alpha 
Social support 6 0.779 
Perceived benefits 8 0.795 
Perceived barriers 8 0.644 
Attitudes – Factor 1 3 0.530 
Attitudes – Factor 2 3 0.511 
Attitudes – Factor 3 2 0.318 
Attitudes – Factor 4 3 0.320 
Attitudes – Factor 5 3 0.298 
Reasons – Factor 1 5 0.788 
Reasons – Factor 2 5 0.714 
Reasons – Factor 3 3 0.717 











Extraction Sums of Squared 
Loadings 













1 2.045 14.607 14.607 2.045 14.607 14.607 1.768 12.628 12.628 
2 1.704 12.174 26.781 1.704 12.174 26.781 1.658 11.841 24.468 
3 1.420 10.146 36.928 1.420 10.146 36.928 1.370 9.782 34.251 
4 1.193 8.523 45.451 1.193 8.523 45.451 1.328 9.488 43.739 
5 1.087 7.764 53.215 1.087 7.764 53.215 1.327 9.476 53.215 
6 .942 6.731 59.946       
7 .932 6.659 66.605       
8 .852 6.088 72.693       
9 .840 5.997 78.690       
10 .745 5.324 84.014       
11 .675 4.822 88.836       
12 .556 3.971 92.807       
13 .533 3.810 96.617       
14 .474 3.383 100.000       





















ka29 taking TB meds is a hassle 0.733     
ka21 clinic appts are more trouble than worth 0.707     
ka28 try hard, will still miss some meds 0.599     
ka27 care about what family and friends think of TB treatment  0.772    
ka25 embarrassed to tell you have TB germ  0.672    
ka24 worry about passing TB germ to loved ones  0.540    
ka26 believe that you have the TB germ   0.683   
ka23 do right thing can avoid getting TB disease   0.575   
ka18 no matter what could still get TB germ    0.702  
ka30 only something really bad would prevent from taking TB meds    0.552  
ka20 you know better than doctor when to stop meds    -0.512  
ka17 BCG vaccine prevents TB disease     0.688 
ka22 do not trust doctor for best care     -0.581 










 Appendix 2 Table 4: Reasons for Missing Medications: Number of Factors and Variance 
Explained 
 
Total Variance Explained 
Component Rotation Sums of Squared Loadings 
Total % of Variance Cumulative % 
dimension0 
1 2.718 15.986 15.986 
2 2.595 15.267 31.253 
3 2.373 13.957 45.210 
4 1.452 8.543 53.753 











 Appendix 2 Table 5: Reasons for Missing Medications: factor loadings for principal 
components analysis with varimax rotation 
 
Rotated Component Matrix 
  Component 1 2 3 4 
11e - felt drug was harmful .795      
11o - knew what was best for you .759      
11d - wanted to avoid side effects .754      
11n - felt good .654      
11p – didn’t feel like taking pills .615      
11q - were drunk or high   .797    
11m - going to drink alcohol   .716    
11f - not want others to notice you taking meds   .619    
11w - you were angry that you have to take the pills   .603    
11x - pills remind you that you have the TB germ   .602    
11b - simply forgot     .713  
11s - were too busy with work/family     .711  
11g - slept through dose time     .682  
11a - pills not fit in with daily routine     .636  
11r - you were away from home     .613  
11l - ran out of pills       .775 
11u - had problems getting the medications       .746 
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 Appendix 2 Table 6: Adherence Imputation Decision Rules – Deterministic Process 
• In cases where participants reported never taking any medications, assign 0% adherence for 
all missing months. 
• We assume that there is a need to stochastically impute data for the month after a clinic visit 
as the participant had the prescription and may have taken the medications. Once clinic visits 
stop and participants don’t have medications, we are assuming 0% adherence for all 
subsequent months.  
• In cases with no MEMS data available, no interview data, and no clinic visits documented, it 
is assumed that adherence for months 2-9 is 0%. Month 1 will be stochastically imputed 
because participants had 1-month supply of medications available to them. 
• In cases where MEMS information is available, use to impute missing interviews as good 
agreement between MEMS and self report was found in this dataset. 
• In cases where there appears to be a conflict in the information provided by interview and by 





Appendix 2 Table 7: Adherence Imputation Algorithm – Stochastic Process 
 
Step Recipient file Donor file 
1. Import files Import recipient file Import donor file 
   
2. Prepare files 2a. Drop records with complete data. 
 
 
2b. Make sure all vars that are the 
same across files start with ‘recip_’ or 
‘donor_’ except for total_months, 
which will be the matching variable. 
 
2c. Create/initialize imputation 
variables: 
imp_donor_PID = ‘.’ (ID of imputing 
donor) 
pattern = character string indicating 
which months have data 
available (e.g., ACDEFH) 
alphabet = ABCDEFGHIJKL 
(character array) 
recip_adhere = average adherence for 






2d. Sort by completion and total 
months available 
2a. Drop records with missing data 
and records with no potential 
recipients. 
 
2b. Make sure all vars that are the 
same across files start with ‘recip_’ 
or ‘donor_’ except for total_months, 
which will be the matching variable. 
 
2c. Create/initialize imputation 
variables: 
randnum = ranuni(32769) (random # 
sequence) 
num_donat = 0 (number of 
donations) 
best_num_donat = ‘.’ 
best_don_PID = ‘.’ 
don_adhere = ‘.’ 
adh_diff = ‘.’ (difference b/w donor 
and recip adherence 
values) 
imp_recip_PID = ‘.’ (ID of imputed 
recipient) 




2d. Sort by completion and total 
months available 
   
3. Subset 
recipients 
Create a reduced recipients file so that 
each cell defined by completion × 
total_months contains only one 
recipient record. 
 
   
4. Merge donors 
and recipients 
 Merge reduced recipient and donor files by completion and total_months. This 
data step is a “one-to-many” merge and will pair the recipient in a given 
completion × total_months cell with all potential donors in that cell. As the 
data step progresses, the object is to find the donor who matches most closely 
on adherence.  
177
 Appendix 2 Table 7: Adherence Imputation Algorithm – Stochastic Process 
 
Step Recipient file Donor file 
   
5. Find donor 
with best fit 
5a. Create an array of donor adherence values based on d_mt1 to d_mt12. 
5b. Calculate don_adhere using recip_pattern and array of adherence values 
5c. Set adh_diff to equal the absolute difference between don_adhere and 
recip_adhere. Check the difference between adherence of each donor and 
recipient until identify the smallest difference that is < cutoff, i.e. <20% or 
30%. If there are multiple donors with the same adherence level that qualify as 
the smallest difference, use the random number generator to select one of 
them. 
   
6. Repeat loop 
for each 
recipient  
Repeat steps 3-5 for each recipient. Retain information such as number of 
donations every time files are merged.  
   
7. Search for 
donors with 1 
month more 
than recipient 
For recipients where no donors were found, repeat step 3 and 4 to merge 
recipient file with donor file where total_months is changed to be 
total_month+1 in donor file, then run steps 5 and 6 on this new merged file. 
   
8. Search for 
donors with 1 
month less than 
recipient 
For recipients where no donors were found, repeat step 3 and 4 to merge 
recipient file with donor file where total_months is changed to be total_month-
1 in donor file, then run steps 5 and 6 on this new merged file. 
  
9. Search for 
donors with 2 
months more 
than recipient 
For recipients where no donors were found, repeat step 3 and 4 to merge 
recipient file with donor file where total_months is changed to be 
total_month+2 in donor file, then run steps 5 and 6 on this new merged file. 
   
10. Search for 
donors with 2 
months less than 
recipient 
For recipients where no donors were found, repeat step 3 and 4 to merge 
recipient file with donor file where total_months is changed to be total_month-
2 in donor file, then run steps 5 and 6 on this new merged file. 
  





For recipients where no donors were identified using the previous steps, 
donors and recipients are match based on having matching neighboring months 
and the months for which data are available should match to within +/- 2 
months. 
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